U.S. patent application number 11/415072 was filed with the patent office on 2006-11-23 for novel megakaryocytic protein tyrosine kinase 1.
This patent application is currently assigned to SUGEN, INC.. Invention is credited to Mikhail Gishizky, Irmingard Sures, Axel Ullrich.
Application Number | 20060263877 11/415072 |
Document ID | / |
Family ID | 22873570 |
Filed Date | 2006-11-23 |
United States Patent
Application |
20060263877 |
Kind Code |
A1 |
Ullrich; Axel ; et
al. |
November 23, 2006 |
Novel megakaryocytic protein tyrosine kinase 1
Abstract
The present invention relates to novel cytoplasmic tyrosine
kinases isolated from megakaryocytes (megakaryocyte kinases or
MKKs) which are involved in cellular signal transduction pathways
and to the use of these novel proteins in the diagnosis and
treatment of disease. The present invention further relates to
specific megakaryocyte kinases, designated MKK1, MKK2 and MKK3, and
their use as diagnostic and therapeutic agents.
Inventors: |
Ullrich; Axel; (Muenchen,
DE) ; Gishizky; Mikhail; (Palo Alto, CA) ;
Sures; Irmingard; (Muenchen, DE) |
Correspondence
Address: |
FOLEY AND LARDNER LLP;SUITE 500
3000 K STREET NW
WASHINGTON
DC
20007
US
|
Assignee: |
SUGEN, INC.
MAX-PLANCK-GESSELLSCHAFT ZUR FONDERUNG DE WISSENSCHAFTEN
E.V.
|
Family ID: |
22873570 |
Appl. No.: |
11/415072 |
Filed: |
May 2, 2006 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
09977260 |
Oct 16, 2001 |
7037677 |
|
|
11415072 |
May 2, 2006 |
|
|
|
08232545 |
Apr 22, 1994 |
6506578 |
|
|
09977260 |
Oct 16, 2001 |
|
|
|
Current U.S.
Class: |
435/326 ;
530/388.26 |
Current CPC
Class: |
C12N 9/1205 20130101;
C07K 2319/00 20130101; C12N 2799/027 20130101; A61K 38/00 20130101;
C07K 16/40 20130101; C12P 21/02 20130101 |
Class at
Publication: |
435/326 ;
530/388.26 |
International
Class: |
C12N 5/06 20060101
C12N005/06; C07K 16/40 20060101 C07K016/40 |
Claims
1. An isolated antibody or antibody fragment that specifically
binds to a megakaryocytic kinase (MKK) protein selected from the
group consisting of MKK1, MKK2 and MKK3.
2. The antibody or antibody fragment of claim 1, wherein said MKK
protein is MKK1.
3. The antibody or antibody fragment of claim 2, wherein said MKK1
comprises the amino acid sequence depicted in SEQ ID NO: 2.
4. The antibody or antibody fragment of claim 1, wherein said MKK
protein is MKK2.
5. The antibody or antibody fragment of claim 4, wherein said MKK2
comprises the amino acid sequence depicted in SEQ ID NO: 4.
6. The antibody or antibody fragment of claim 1, wherein said MKK
protein is MKK3.
7. The antibody or antibody fragment of claim 6, wherein said MKK1
comprises the amino acid sequence depicted in SEQ ID NO: 6.
8. The antibody or antibody fragment of claim 1, wherein said
antibody or antibody fragment is monoclonal.
9. The antibody or antibody fragment of claim 1, wherein said
antibody or antibody fragment is chimeric.
10. A hybridoma that produces the antibody or antibody fragment of
claim 1.
Description
CROSS-REFERENCE TO RELATED PATENT APPLICATIONS
[0001] This application is a Division of U.S. application Ser. No.
09/977,260, filed Oct. 16, 2001, incorporated herein by reference
in its entirety, which is a Division of U.S. application Ser. No.
08/232,545, filed Apr. 22, 1994, incorporated herein by reference
in its entirety.
BACKGROUND OF THE INVENTION
[0002] 1. Introduction
[0003] The present invention relates to novel cytoplasmic tyrosine
kinases isolated from megakaryocytes (megakaryocyte kinases or
MKKs) which are involved in cellular signal transduction pathways
and to the use of these novel proteins in the diagnosis and
treatment of disease.
[0004] The present invention further relates to specific
megakaryocyte kinases, designated MKK1, MKK2 and MKK3, and their
use as diagnostic and therapeutic agents.
[0005] 2. Background
[0006] Cellular signal transduction is a fundamental mechanism
whereby external stimuli that regulate diverse cellular processes
are relayed to the interior of cells. These processes include, but
are not limited to, cell proliferation, differentiation and
survival. Many tyrosine kinases are expressed in postmitotic, fully
differentiated cells, particularly in the case of hematopoietic
cells, and it seems likely that these proteins are involved in
specialized cellular functions that are specific for the cell types
in which they are expressed. (Eiseman, E. and J. B. Bolen, Cancer
cells 2(10):303-310, 1990). A central feature of signal
transduction is the reversible phosphorylation of certain proteins
(for reviews, see Posada, J. and Cooper, J. A., 1992, Mol. Biol.
Cell 3:583-392; Hardie, D. G., 1990, Symp. Soc. Exp. Biol.
44:241-255). The phosphorylation state of a protein is modified
through the reciprocal actions of tyrosine kinases (TKs), which
function tophosphorylate proteins, and tyrosine phosphatases (TPs),
which function to dephosphorylate proteins. Normal cellular
function requires a delicate balance between the activities of
these two types of enzyme.
[0007] Phosphorylation of cell surface tyrosine kinases, stimulates
a physical association of the activated receptor with intracellular
target molecules. Some of the target molecules are in turn
phosphorylated. Other target molecules are not phosphorylated, but
assist in signal transmission by acting as adapter molecules for
secondary signal transducer proteins.
[0008] The secondary signal transducer molecules generated by
activated receptors result in a signal cascade that regulates cell
functions such as cell division or differentiation. Reviews
describing intracellular signal transduction include Aaronson, S.
A., Science 254:1146-1153, 1991; Schlessinger, J. Trends Biochem.
Sci. 13:443-447, 1988; and Ullrich, A., and Schlessinger, J. Cell
61:203-212, 1990.
[0009] Receptor tyrosine kinases are composed of at least three
domains: an extracellular ligand binding domain, a transmembrane
domain and a cytoplasmiccatalytic domain that can phosphorylate
tyrosine residues. The intracellular, cytoplasmic, nonreceptor
protein tyrosine kinases may be broadly defined as those protein
tyrosine kinases which do not contain a hydrophobic, transmembrane
domain. Bolen (Oncogene, vol. 8, pgs. 2025-2031 (1993)) reports
that 24 individual protein tyrosine kinases comprising eight
different families of non-receptor protein tyrosine kinases have
been identified: Ab1/Arg; Jak1/Jak2/Tyk2; Fak; Fes/Fps; Syk/Zap;
Tsk/Tec/Atk; Csk; and the Src group, which includes the family
members Src, Yes, Fyn, Lyn, Lck, Blk, Hck, Fgr and Yrk. All of the
non-receptor protein tyrosine kinases are thought to be involved in
signaling pathways that modulate growth and differentiation. Bolen,
supra, suggests that half of the nonreceptor protein tyrosine
kinases have demonstrated oncogenic potential and half appear to be
primarily related to suppressing the activity of Src-related
protein kinases and could be classified as anti-oncogenes.
[0010] While distinct in their overall molecular structure, each
member of a given morphotypic family of cytoplasmic protein
tyrosine kinases shares sequence homology in certain non-catalytic
domains in addition to sharing sequence homology in the catalytic
kinase domain. Examples of defined non-catalytic domains include
the SH2 (SRC homology domain 2; Sadowski, I et al., Mol. Cell.
Biol. 6:4396-4408; Kock, C. A. et al., 1991, Science 252:668-674)
domains, SH3 domains (Mayer, B. J. et al., 1988, Nature 332:269272)
and PH domains (Musacchio et al., TIBS 18:343-348 (1993). These
non-catalytic domains are thought to be important in the regulation
of protein-protein interactions during signal transduction (Pawson,
T. and Gish, G., 1992, Cell 71:359-362).
[0011] While the metabolic roles of cytoplasmic protein tyrosine
kinases are less well understood than that of the receptor-type
protein tyrosine kinases, significant progress has been made in
elucidating some or the processes in which this class of molecules
is involved. For example, members of the src family, lck and fyn,
have been shown to interact with CD4/CD8 and the T cell receptor
complex, and are thus implicated in T cell activation, (Veillette,
A. Davidson, D., 1992, TIG 8:61-66). Some cytoplasmic protein
tyrosine kinases have been linked to certain phases of the cell
cycle (Morgan, D. O. et al., 1989, Cell 57:775-786; Kipreos, E. T.
et al., 1990, Science 248:217-220; Weaver et al., 1991, Mol. Cell.
Biol. 11:4415-4422), and cytoplasmic protein tyrosine kinases have
been implicated in neuronal and hematopoietic development (Maness,
P., 1992, Dev. Neurosci 14:257-270 and Rawlings et al., Science
261:358-361 (1993)). Deregulation of kinase activity through
mutation or overexpression is a well-established mechanism
underlying cell transformation (Hunter et al., 1965, supra; Ullrich
et al., supra).
[0012] A variety of cytoplasmic tyrosine kinases are expressed in,
and may have important functions in, hematopoietic cells including
src, lyn, fyn, blk, lck, csk and hck. (Eisenian, E. and J. B.
Bolen, Cancer Cells 2(10):303-310, 1990). T-cell activation, for
example, is associated with activation of lck. The signaling
activity of lyn may be stimulated by binding of allergens to IgE on
the surface of basophils. (Eisenian, supra).
[0013] Abnormalities in tyrosine kinase regulated signal
transduction pathways can result in a number of disease states. For
example, mutations in the cytoplasmic tyrosine kinase atk (also
called btk) are responsible for the x-linked agammaglobulinemia,
(Ventrie, D., et al., Nature 361:226-23, 1993). This defect appears
to prevent the normal differentiation of pre-B cells to mature
circulating B cells and results in a complete lack of serum
immunoglobulins of all isotypes. The cytoplasmic tyrosine kinase
Zap-70 has been suggested as indispensable for the development of
CD8 single-positive T cells as well as for signal transduction and
function of single positive CD4 T cells, and lack of this protein
leads of an immunodeficiency disease in humans, (Arpala, E., et
al., Cell 76:1-20, 1994). Gene knockout experiments in mice suggest
a role for src in the regulation of osteociast function and bone
remodeling as these mice develop osteopetrosis. (Soriano et al.,
Cell 64:693-702, 1991 and Lowe et al., PNAS (in press)).
[0014] Megakaryocytes are large cells normally present in bone
marrow and spleen and are the progenitor cell for blood platelets.
Megakaryocytes are associated with such disease states as acute
megakaryocytic leukemia (Lu et al., Cancer Genet Cvtoaenet,
67(2):81-89 (1993) and Moody et al., Pediatr Radiol.
19(6-7):486-488 (1989)), a disease that is difficult to diagnose
early and which is characterized by aberrant proliferation of
immature cells or "blasts;" myelofibrosis (Smith et al., Crit Rev
Oncol Hematol. 10(4 :305-314 (1990) and Marino, J. Am. Osteopath
Assoc. 10:1323-1326 (1989)), an often fatal disease where the
malignant cell may be of megakaryocytic lineage and may be mediated
by platelet or megakaryocyte growth factors; acute megakaryocytic
myelosis (Fohlmeister et al., Haematologia 19(2):151-160 (1986)) a
rapidly fatal disease characterized by megakaryocytic proliferation
and the appearance of immature megakaryocytes in the circulation;
and acute myelosclerosis (Butler et al., Cancer 49(12):2497-2499
(1982) and Bearman et al., Cancer 43(1):279-93 (1979)) a
myeloproliferative syndrome where the marrow is characterized by
atypical megakaryocytes.
[0015] Platelets play a key role in the regulation of blood
clotting and wound healing, as well as being associated with such
disease conditions as thrombocytopenia, atherosclerosis, restenosis
and leukemia. Several receptor tyrosine kinases have been
identified in human megakaryocytes including c-kit, blg and blk.
(Hoffman, H., Blood 74:1196-1212, 1989; Long, M. W., Stem Cells
11:33-40, 1993; Zaebo, K. M., et al., Cell 63:213-224,1990).
Cytoplasmic tyrosine kinases of human megakaryocytic origin have
also been reported. (Bennett et al., Journal of Biological
Chemistry 289(2):1068-1074, 1994; Lee et al., Gene 1-5, 1993; and
Sakano et al., Oncogene 9:1155-1161 (1994)).
SUMMARY OF THE INVENTION
[0016] The present invention relates to novel, cytoplasmic tyrosine
kinases isolated from megakaryocytes (megakaryocyte kinases or
MKKs) which are involved in cellular signal transduction pathways.
Particular MKKs described herein are referred to as MKK1, MKK2, and
MKK3. The complete nucleotide sequences encoding MKK1, MKK2, and
MKK3 are disclosed herein, and provide the basis for several
aspects of the invention hereinafter described.
[0017] The present invention is based, in part, upon the discovery
that MKK1, MKK2, and MKK3 have amino acid and structural homology,
respectively, to the PTKs csk (Brauninger et al. Gene, 110:205-211
(1992) and Brauninger et al., Oncoaene, 8:1365-1369 (1993)),
atk/btk, tec and tsk (Vetrie et al., Nature 361:226-233 (1993);
Mano et al., Oncogene 8:417-424 (1993) and Heyeck et al., PNAS USA
90:669-673, 1993, respectively) and fyn (Kawakami et al. Mol. Cell.
Bio 6:4195-4201, 1986)).
[0018] The present invention also relates, in part, to nucleotide
sequences and expression vectors encoding MKKs. Also described
herein are methods of treatment and diagnosis of diseases resulting
from abnormalities in signal transduction pathways in which MKKs
are involved.
[0019] The MKK sequences disclosed herein may be used to detect and
quantify levels of MKK mRNA in cells and furthermore for diagnostic
purposes for detection of expression of MKKs in cells. For example,
an MKK sequence may be used in hybridization assays of biopsied
tissue to diagnose abnormalities in gene expression associated with
a transformed phenotype.
[0020] Also disclosed herein are methods of treatment of diseases
or conditions associated with abnormalities in signal transduction
pathways in megakaryocytes. Such abnormalities can result in, for
example, under production of mature, differentiated cells,
inappropriate proliferation of immature cells or modulation of
activity of other important cellular functions.
[0021] Anti-MKK antibodies may be used for diagnostic purposes for
the detection of MKKs in tissues and cells. Anti-MKK antibodies may
also be used for therapeutic purposes, for example, in neutralizing
the activity of an MKK associated with a signal transduction
pathway.
[0022] Oligonucleotide sequences, including anti-sense RNA and DNA
molecules and ribozymes, designed to inhibit the translation of MKK
mRNA, may be used therapeutically in the treatment of disease
states associated with aberrant expression of MKKs. In a particular
embodiment of the invention described by way of Example 9 herein,
an anti-MKK1 antisense molecule is used to inhibit MKK-1 protein
synthesis resulting in reduced megakaryocyte growth and
differentiation.
[0023] Proteins, peptides and organic molecules capable of
modulating activity of MKKs may be used therapeutically in the
treatment of disease states associated with aberrant expression of
MKKs. Alternatively, proteins, peptides and organic molecules
capable of modulating activity of MKKs maybe used therapeutically
to enhance normal activity levels of MKKs. For example, small
molecules found to stimulate MKK1 activity in megakaryocytes may be
used for ex vivo culturing of megakaryocytes intended for
autologous treatment of patients receiving chemotherapy or other
therapies which deplete megakaryoctyes or platelets, or in the
treatment of thrombocytopenia.
BRIEF DESCRIPTION OF THE DRAWINGS
[0024] FIGS. 1A and 1B. Human MKK1 nucleotide sequence (SEQ ID
NO:1) and deduced amino acid sequence (SEQ ID NO:2). Marked regions
show the signal sequence, the SH2 and SH3 domains, and the
catalytic domain.
[0025] FIGS. 2A and 2B. Human MKK2 nucleotide sequence (SEQ ID
NO:3) and deduced amino acid sequence (SEQ ID NO:4). Marked regions
show the signal sequence, the pleckstrin homology domain (PH), the
proline rich sequences following the PH domain, the SH2 and SH3
domains, and the catalytic domain.
[0026] FIGS. 3A and 3B. Human MKK3 nucleotide sequence (SEQ ID
NO:5) and deduced amino acid sequence (SEQ ID NO:6). Marked regions
show the signal sequence, the SH2 and SH3 domains, and the
catalytic domain.
[0027] FIG. 4. Expression of MKK1 and MKK2 in human and rodent cell
lines.
[0028] FIG. 5. Immunoprecipitation (i.p.) of in vitro transcribed
and translated MKK1 and MKK2 proteins. Samples in lanes designated
1 through 9 are as follows: 1. MKK1 i.p. with anti-carboxy terminus
MKK1 Ab, 2. and 3. MKK1 i.p. with anti-amino terminus MKK1 Ab, 4.
MKK1 i.p. with rabbit pre immune sera, 5. MKK2 i.p. with rabbit pre
immune sera, 6, and, 7. MKK2 i.p. with anti-carboxy terminus MKK2
Ab, 8. MKK1 in vitro transcribed/translated protein without i.p.,
9. MKK2 in vitro transcribed/translated protein without i.p.
[0029] FIGS. 6A and 6B. FIGS. 6A-6B illustrate anti-sense MMK1
expression suppresses AChE Production in primary murine bone marrow
cultures. FIG. 6A illustrates AChE production. FIG. 6B illustrates
MKK1 protein expression.
[0030] FIG. 7. MKK2 and MKK3 autophosphorylate and
transphosphorylate proteins when expressed in bacteria. Lanes 2, 4,
and 6 represent non-induced bacteria expressing MKK1, MKK2, MKK3,
respectively. Lanes 1, 3, and 5 represent induced bacteria
expressing MKK1, MKK2, MKK3, respectively.
[0031] FIG. 8. MKK expression constructs.
[0032] FIG. 9. Shared amino acid sequence homology of MKK1 SEQ ID
NO: 2 and csk SEQ ID NO: 7.
[0033] FIGS. 10A and 10B SEQ ID NOS 4, 8-10, respectively, in order
of appearance. Shared amino acid sequence homology of MKK2 and
atk/btk.
[0034] FIGS. 11A, 11B, 11C and 11D SEQ ID NOS 6, 11-19,
respectively, in order of appearance. Shared amino acid sequence
homology of MKK3 and src tyrosine kinase family members.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0035] The present invention relates to novel, cytosolic
megakaryocytic kinases referred to herein as "MKKs," and in
particular to megakaryocyte kinase 1 (MKK1), megakaryocyte kinase 2
(MKK2), which are expressed in human megakaryocytic cell lines, and
megakaryocyte kinase 3 (MKK3).
[0036] As used herein, MKK is a term which refers to MKK1, MKK2 and
MKK3 from any species, including, bovine, ovine, porcine, equine,
murine and preferably human, in naturally occurring-sequence or in
variant form, or from any source, whether natural, synthetic, or
recombinant. A preferred MKK variant is one having at least 80%
amino acid homology, a particularly preferred MKK variant is one
having at least 90% sequence homology and another particularly
preferred MKK variant is one having at least 95% amino acid
homology to the naturally occurring MKK.
[0037] MKK1 is a cytosolic tyrosine kinase of molecular weight 58
kD, as determined by SDS gel electrophoresis, having homology to
the TK csk (Partanen, et al., Oncogene 6:2013-2018 (1991) and Nada
et al., Nature 351:69-72 (1991)) in the intervening sequences of
its catalytic domain, the SH2 and SH3 domains, and other
non-catalytic regions and like csk, lacks regulatory
phosphorylation sites corresponding to c-src tyrosines 416 and 527.
MKK1 also lacks an amino-terminal myristylation site.
[0038] Csk is a recently described novel cytoplasmic TK that seems
to play a key role in regulation of signal transduction in
hematopoietic and neural development. For example csk has been
shown to negatively regulate members of the src family of TKs,
including c-src, lck, and fyn, through its ability to phosphorylate
regulatory tyrosines. (Bergman et al., The EMBO Journal
11(8)8:2919-2924 (1992) and Sabe et al., Molecular and Cellular
Biology 12(10):4706-4713 (1992)). Autero et al., (Molecular and
Cellular Biology 14(2):1308-1321 (1994)) have reported that csk
positively regulates a phosphatase, CD45, that is key to T-cell
activity. Csk mediated phosphorylation of CD45 phosphotyrosine
phosphatase (PTPase) caused a several fold increase in its PTPase
activity. Csk appears to play a role as a regulator of the sequence
of both phosphorylation and dephosphorylation events culminating in
cell activation and proliferation.
[0039] Defective expression of csk in mouse embryos results in
defects in the neural tube with subsequent death between day 9 and
day 10 of gestation, with cells derived from these embryos
exhibiting an order of magnitude increase in activity of src kinase
(Nada et al., Cell 73:1125-1135 (1993)). Overexpression of csk in
transformed rat 3Y1 fibroblasts was shown to cause reversion to
normal phenotypes (Sabe et al., Molecular and Cellular Biology
12:4706-4713 (1992)).
[0040] MKK1 has 54% homology with csk at the amino acid level and
structural similarity to csk, i.e., the lack of regulatory
phosphorylation sites and the lack of an amino-terminal
myristylation site. Experimental data, see Section 9, show that
expression of human antisense MKK 1 sequences inhibits synthesis of
murine MKK 1, which inhibition is associated with a reduction of
proliferation of megakaryocytes in vitro. Based upon the
experimental data in Section 9 and amino acid and structural
homology with csk, MKK1 appears to play a regulatory role in the
growth and differentiation of megakaryocytes and perhaps neural
tissues based on its expression in those tissues.
[0041] MKK2 is a novel cytosolic tyrosine kinase of molecular
weight 78 kD, as determined by SDS gel electrophoresis, having
homology to the tec subfamily of TKs which also incudes tsk and
atk/btk. Like the tec subfamily, MKK2 lacks an amino-terminal site
for myristylation and has a putative pleckstrin homology binding
domain located 5' to the SH3 domain (Musacchio et al., TIBS
18:343-348 (1993)). The pleckstrin homology (PH) domain has been
found in a number of proteins with diverse cellular functions and
is abundant in proteins involved in signal transduction pathways.
Musacchio et al., supra suggest that the PH domain may be involved
in molecular recognition similarly to SH2 and SH3 domains.
[0042] The tec family of tyrosine kinases appear to play roles in
cellular differentiation and include family members tec, a kinase
which may be specifically involved in the cell growth of
hepatocytes or hepatocarcinogenesis (Mano et al., supra); tsk,
which may play a role in early T-lymphocyte differentiation (Heyek
et al., PNAS USA 90:669-673 (1993)) and atk/btk. Aberrant
expression of atk/btk has been shown to be responsible for X-linked
agammaglobulinemia (XLA), a human disease resulting from a
developmental block in the transition from preB cells to mature B
cells (Ventrie, D. et al., supra).
[0043] MKK2 has 50% homology to atkibtk at the amino acid level and
structural similarity to tec family members, i.e., the presence of
the SH2, SH3 and PH domains and the lack of an amino-terminal site
for myristylation and the carboxyl site of tyrosine phosphorylation
found in family members. Based upon the amino acid homology and
structural similarity to tec family members which play roles in
cellular differentiation, MKK2 may play a role in the
differentiation of megakaryoctyes.
[0044] MKK3 is a novel cytosolic tyrosine kinase of molecular
weight 58 kD, as determined by SDS gel electrophoresis, having
homology to the TK fyn. MKK3 does not have a myristylation sites.
MKK3 does have a putative regulatory cite at tyr 387 but the
surrounding 12 amino acids are not identical with other members of
the src subfamily that share highly conserved sequences in this
region. MKK3 has 47% homology with fyn at the amino acid level.
[0045] The fyn gene was originally characterized in normal human
fibroblast and endothelial cells, but it is also expressed in a
variety of other cell types. Alternative splicing of fyn has been
shown to yield two distinct transcripts, both coding for
enzymatically active forms of the kinases.
[0046] MKK sequences could be used diagnostically to measure
expression of MKKs in disease states, such as for example leukemia,
where abnormal proliferation of immature myeloid cells occurs, or
where abnormal differentiation of megakaryocytes occurs. MKKs could
also be used therapeutically in the treatment of disease states
involving abnormal proliferation or differentiation through
interruption of signal transduction by modulation of protein
tyrosine kinases.
[0047] The nucleotide and deduced amino acid sequence of human MKK
1, MKK2, and MKK3 are shown in FIGS. 1A-1B (SEQ ID NOS 1-2), 2A-2B
(SEQ ID NOS 3-4) and 3A-3B (SEQ ID NOS 5-6), respectively. FIGS. 9
(SEQ ID NOS 2 and 7, respectively, in order of appearance), 10A-10B
(SEQ ID NOS 4, 8-10, respectively, in order of appearance) and
11A-11D (SEQ ID NOS 6, 11-19, respectively, in order of appearance)
show the shared sequence homology between MKKs and related tyrosine
kinases.
The MKK Coding Sequences
[0048] The nucleotide coding sequence and deduced amino acid
sequence of the human MKK1, MKK2, and MKK3 genes are depicted in
FIGS. 1A-1B (SEQ ID NOS 1-2), 2A-2B (SEQ ID NOS 3-4) and 3A-3B (SEQ
ID NOS 5-6), respectively. In accordance with the invention, any
nucleotide sequence which encodes the amino acid sequence of an MKK
gene product can be used to generate recombinant molecules which
direct the expression of an MKK.
[0049] In a specific embodiment described herein, the human MKK1,
MKK2, and MKK3 genes were isolated by performing polymerase chain
reactions (PCR) in combination with two degenerate oligonucleotide
primer pools that were designed on the basis of highly conserved
sequences within the kinase domain of receptor tyrosine kinases
corresponding to the amino acid sequence HRDLAA (residues 350-355
of SEQ ID NO: 2) (sense primer) and SDVWSF/Y (SEQ ID NO: 24)
(antisense primer) (Hanks et al., 1988). The MKK cDNAs were
synthesized by reverse transcription of poly-A RNA from the human
K-562 cell line, ATCC accession number CCL 243, or from the Meg 01
cell line, (Ogura et al., Blood 66:1384 (1985)).
[0050] The PCR fragments were used to screen a lambda gt11 library
of human fetal brain. For each individual MKK, several overlapping
clones were identified. The composite of the cDNA clones for MKK1,
MKK2, and MKK3 are depicted in FIGS. 1A-1B (SEQ ID NOS 1-2), 2A-2B
(SEQ ID NOS 3-4), and 3A-3B (SEQ ID NOS 5-6), respectively.
[0051] Further characterization of the individual MKKs is found
infra.
Expression of MKK
[0052] In accordance with the invention, MKK polynucleotide
sequences which encode MKKs, peptide fragments of MKKs, MKK fusion
proteins or functional equivalents thereof, may be used to generate
recombinant DNA molecules that direct the expression of MKK
protein, MKK peptide fragment, fusion proteins or a functional
equivalent thereof, in appropriate host cells. Such MKK
polynucleotide sequences, as well as other polynucleotides which
selectively hybridize to at least a part of such MKK
polynucleotides or their complements, may also be used in nucleic
acid hybridization assays, Southern and Northern blot analyses,
etc.
[0053] Due to the inherent degeneracy of the genetic code, other
DNA sequences which encode substantially the same or a functionally
equivalent amino acid sequence, may be used in the practice of the
invention for the cloning and expression of the MKK protein. Such
DNA sequences include those which are capable of hybridizing to the
human MKK sequence under stringent conditions. The phrase
"stringent conditions" as used herein refers to those hybridizing
conditions that (1) employ low ionic strength and high temperature
for washing, for example, 0.015 M NaC1/0.0015 M sodium citrate/0.1%
SDS at 50.degree. C.; (2) employ during hybridization a denaturing
agent such as formamide, for example, 50% (vol/vol) formamide with
0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50
mM sodium phosphate buffer at pH 6.5 with 750 mM NaCl, 75 mM sodium
citrate at 42.degree. C.; or (3) employ 50% formamide, 5.times.SSC
(0.75 M NaCl, 0.075 M Sodium pyrophosphate, 5.times. Denhardt's
solution, sonicated salmon sperm DNA (50 g/ml), 0.1% SDS, and 10%
dextran sulfate at 42.degree. C., with washes at 42.degree. C. in
0.2.times.SSC and 0.1% SDS.
[0054] Altered DNA sequences which may be used in accordance with
the invention include deletions, additions or substitutions of
different nucleotide residues resulting in a sequence that encodes
the same or a functionally equivalent gene product. The gene
product itself may contain deletions, additions or substitutions of
amino acid residues within an MKK sequence, which result in a
silent change thus producing a functionally equivalent MKK. Such
amino acid substitutions may be made on the basis of similarity in
polarity, charge, solubility, hydrophobicity, hydrophilicity,
and/or the amphipatic nature of the residues involved. For example,
negatively charged amino acids include aspartic acid and glutamic
acid; positively charged amino acids include lysine and arginine;
amino acids with uncharged polar head groups having similar
hydrophilicity values include the following: leucine, isoleucine,
valine; glycine, alanine; asparagine, glutamine; serine, threonine;
phenylalanine, tyrosine.
[0055] The DNA sequences of the invention may be engineered in
order to alter an MKK coding sequence for a variety of ends
including but not limited to alterations which modify processing
and expression of the gene product. For example, mutations may be
introduced using techniques which are well known in the art, e.g.,
site-directed mutagenesis, to insert new restriction sites, to
alter glycosylation patterns, phosphorylation, etc.
[0056] In another embodiment of the invention, an MKK or a modified
MKK sequence may be ligated to a heterologous sequence to encode a
fusion protein. For example, for screening of peptide libraries for
inhibitors of MKK activity, it may be useful to encode a chimeric
MKK protein expressing a heterologous epitope that is recognized by
a commercially available antibody. A fusion protein may also be
engineered to contain a cleavage site located between an MKK
sequence and the heterologous protein sequence, so that the MKK may
be cleaved away from the heterologous moiety.
[0057] In an alternate embodiment of the invention, the coding
sequence of an MKK could be synthesized in whole or in part, using
chemical methods well known in the art. See, for example, Caruthers
et al., 1980, Nuc. Acids Res. Symp. Ser. 7:215-233; Crea and Horn,
180, Nuc. Acids Res. 9(10):2331; Matteucci and Caruthers, 1980,
Tetrahedron Letters 21:719; and Chow and Kempe, 1981, Nuc. Acids
Res. 9(12):2807-2817. Alternatively, the protein itself could be
produced using chemical methods to synthesize an MKK amino acid
sequence in whole or in part. For example, peptides can be
synthesized by solid phase techniques, cleaved from the resin, and
purified by preparative high performance liquid chromatography.
(e.g., see Creighton, 1983, Proteins Structures And Molecular
Principles, W. H. Freeman and Co., N.Y. pp. 50-60). The composition
of the synthetic peptides may be confirmed by amino acid analysis
or sequencing (e.g., the Edman degradation procedure; see
Creighton, 1983, Proteins Structures and Molecular Principles, W.
H. Freeman and Co., N.Y., pp. 34-49.
[0058] In order to express a biologically active MKK, the
nucleotide sequence coding for MKK, or a functional equivalent, is
inserted into an appropriate expression vector, i.e., a vector
which contains the necessary elements for the transcription and
translation of the inserted coding sequence. The MKK gene products
as well as host cells or cell lines transfected or transformed with
recombinant MKK expression vectors can be used for a variety of
purposes. These include but are not limited to generating
antibodies (i.e., monoclonal or polyclonal)that competitively
inhibit activity of an MKK and neutralize its activity. Anti-MKK
antibodies may be used in detecting and quantifying expression of
an MKK in cells and tissues.
Expression Systems
[0059] Methods which are well known to those skilled in the art can
be used to construct expression vectors containing an MKK coding
sequence and appropriate transcriptional/translational control
signals. These methods include in vitro recombinant DNA techniques,
synthetic techniques and in vivo recombination/genetic
recombination. See, for example, the techniques described in
Maniatis et al., 1989, Molecular Cloning A Laboratory Manual, Cold
Spring Harbor Laboratory, N.Y. and Ausubel et al., 1989, Current
Protocols in Molecular Biology, Greene Publishing Associates and
Wiley Interscience, N.Y.
[0060] A variety of host-expression vector systems may be utilized
to express an MKK coding sequence. These include but are not
limited to microorganisms such as bacteria transformed with
recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression
vectors containing an MKK coding sequence; yeast transformed with
recombinant yeast expression vectors containing an MKK coding
sequence; insect cell systems infected with recombinant virus
expression vectors (e.g., baculovirus) containing an MKK coding
sequence; plant cell systems infected with recombinant virus
expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco
mosaic virus, TMV) or transformed with recombinant plasmid
expression vectors (e.g., Ti plasmid) containing an MKK coding
sequence; or animal cell systems. The expression elements of these
systems vary in their strength and specificities. Depending on the
host/vector system utilized, any of a number of suitable
transcription and translation elements, including constitutive and
inducible promoters, may be used in the expression vector. For
example, when cloning in bacterial systems, inducible promoters
such as pL of bacteriophage .lamda., plac, ptrp, ptac (ptrp-lac
hybrid promoter) and the like may be used; when cloning in insect
cell systems, promoters such as the baculovirus polyhedrin promoter
may be used; when cloning in plant cell systems, promoters derived
from the genome of plant cells (e.g., heat shock promoters; the
promoter for the small subunit of RUBISCO; the promoter for the
chlorophyll a/b binding protein) or from plant viruses (e.g., the
35S RNA promoter of CaMV; the coat protein promoter of TMV) may be
used; when cloning in mammalian cell systems, promoters derived
from the genome of mammalian cells (e.g., metallothionein promoter)
or from mammalian viruses (e.g., the adenovirus late promoter; the
vaccinia virus 7.5 K promoter) may be used; when generating cell
lines that contain multiple copies of an MKK DNA, SV40-, BPV- and
EBV-based vectors may be used with an appropriate selectable
marker.
[0061] In bacterial systems a number of expression vectors may be
advantageously selected depending upon the use intended for the MKK
expressed. For example, when large quantities of MKK1 are to be
produced for the generation of antibodies, vectors which direct the
expression of high levels of fusion protein products that are
readily purified may be desirable. Such vectors include but are not
limited to the E. coli expression vector pUR278 (Ruther et al.,
1983, EMBO J. 2:1791), in which the MKK1 coding sequence may be
ligated into the vector in frame with the lac Z coding region so
that a hybrid AS-lac Z protein is produced; pIN vectors (Inouye
& Inouye, 1985, Nucleic acids Res. 13:3101-3109; Van Heeke
& Schuster, 1989, J. Biol. Chem. 264:5503-5509); and the like.
pGEX vectors may also be used to express foreign polypeptides as
fusion proteins with glutathione S-transferase (GST). In general,
such fusion proteins are soluble and can easily be purified from
lysed cells by adsorption to glutathione-agarose beads followed by
elution in the presence of free glutathione. The pGEX vectors are
designed to include thrombin or factor Xa protease cleavage sites
so that the cloned polypeptide of interest can be released from the
GST moiety.
[0062] In yeast, a number of vectors containing constitutive or
inducible promoters may be used. For a review see, Current
Protocols in Molecular Biology, Vol. 2, 1988, Ed. Ausubel et al.,
Greene Publish. Assoc. & Wiley Interscience, Ch. 13; Grant et
al., 1987, Expression and Secretion Vectors for Yeast, in Methods
in Enzymology, Ed. Wu & Grossman, 1987, Acad. Press, N.Y.
153:516-544; Glover, 1986, DNA Cloning, Vol. II, IRL Press, Wash.,
D.C., Ch. 3; and Bitter, 1987, Heterologous Gene Expression in
Yeast, Methods in Enzymology, Eds. Berger & Kimmel, Acad.
Press, N.Y. 152:673-684; and The Molecular Biology of the Yeast
Saccharomyces, 1982, Eds. Strathern et al., Cold Spring Harbor
Press, Vols. I and II.
[0063] In cases where plant expression vectors are used, the
expression of an MKK coding sequence may be driven by any of a
number of promoters. For example, viral promoters such as the 35S
RNA and 19S RNA promoters of CaMV (Brinson et al., 1984, Nature
310:511-514), or the coat protein promoter of TMV (Takamatsu et
al., 1987, EMBO J. 6:307-311) may be used; alternatively, plant
promoters such as the small subunit of RUBISCO (Coruzzi et al.,
1984, EMBO J. 3:1671-1680; Broglie et al., 1984, Science
224:838-843); or heat shock promoters, e.g., soybean hsp 17.5-E or
hsp 17.3-B (Gurley et al., 1986, Mol. Cell. Biol. 6:559-565) may be
used. These constructs can be introduced into plant cells using Ti
plasmids, Ri plasmids, plant virus vectors, direct DNA
transformation, microinjection, electroporation, etc. For reviews
of such techniques see, for example, Weissbach & Weissbach,
1988, Methods for Plant Molecular Biology, Academic Press, NY,
Section VIII, pp. 421-463; and Grierson & Corey, 1988, Plant
Molecular Biology, 2d Ed., Blackie, London, ch. 7-9.
[0064] An alternative expression system which could be used to
express an MKK is an insect system. In one such system, Autographa
californica nuclear polyhidrosis virus (AcNPV) is used as a vector
to express foreign genes. The virus grows in Spodoptera frugiperda
cells. An MKK coding sequence may be cloned into non-essential
regions (for example the polyhedrin gene) of the virus and placed
under control of an AcNPV promoter (for example, the polyhedrin
promoter). Successful insertion of an MKK coding sequence will
result in inactivation of the polyhedrin gene and production of
non-occluded recombinant virus (i.e., virus lacking the
proteinaceous coat coded for by the polyhedrin gene). These
recombinant viruses are then used to infect Spodoptera frugiperda
cells in which the inserted gene is expressed. (e.g., see Smith et
al., 1983, J. Viol. 46:584; Smith, U.S. Pat. No. 4,215,051).
[0065] In mammalian host cells, a number of viral based expression
systems may be utilized. In cases where an adenovirus is used as an
expression vector, an MKK coding sequence may be ligated to an
adenovirus transcription/translation control complex, e.g., the
late promoter and tripartite leader sequence. This chimeric gene
may then be inserted in the adenovirus genome by in vitro or in
vivo recombination. Insertion in a non-essential region of the
viral genome (e.g., region E1 or E3) will result in a recombinant
virus that is viable and capable of expressing an MKK in infected
hosts. (e.g., See Logan & Shenk, 1984, Proc. Natl. Acad. Sci.
(USA) 81:3655-3659). Alternatively, the vaccinia 7.5 K promoter may
be used. (See, e.g., Mackett et al., 1982, Proc. Natl. Acad. Sci.
(USA) 79:7415-7419; Mackett et al., 1984, J. Virol. 49:857-864;
Panicali et al., 1982, Proc. Natl. Acad. Sci. 79:4927-4931).
[0066] Specific initiation signals may also be required for
efficient translation of an inserted MKK coding sequences. These
signals include the ATG initiation codon and adjacent sequences. In
cases where an entire MKK gene, including its own initiation codon
and adjacent sequences, is inserted into the appropriate expression
vector, no additional translational control signals may be needed.
However, incases where only a portion of an MKK coding sequence is
inserted, exogenous translational control signals, including the
ATG initiation codon, must be provided. Furthermore, the initiation
codon must be in phase with the reading frame of an MKK coding
sequence to ensure translation of the entire insert. These
exogenous translational control signals and initiation codons can
be of a variety of origins, both natural and synthetic. The
efficiency of expression may be enhanced by the inclusion of
appropriate transcription enhancer elements, transcription
terminators, etc. (see Bittner et al., 1987, Methods in Enzymol.
153.516-544).
[0067] In addition, a host cell strain may be chosen which
modulates the expression of the inserted sequences, or modifies and
processes the gene product in the specific fashion desired. Such
modifications (e.g., glycosylation) and processing (e.g., cleavage)
of protein products may be important for the function of the
protein. Different host cells have characteristic and specific
mechanisms for the post-translational processing and modification
of proteins. Appropriate cells lines or host systems can be chosen
to ensure the correct modification and processing of the foreign
protein expressed. To this end, eukaryotic host cells which possess
the cellular machinery for proper processing of the primary
transcript, glycosylation, and phosphorylation of the gene product
may be used. Such mammalian host cells include but are not limited
to CHO, VERO, BHK, HeLa, COS, MDCK, 293, WI38, etc.
[0068] For long-term, high-yield production of recombinant
proteins, stable expression is preferred. For example, cell lines
which stably express an MKK may be engineered. Rather than using
expression vectors which contain viral origins of replication, host
cells can be transformed with MKK DNA controlled by appropriate
expression control elements (e.g., promoter, enhancer, sequences,
transcription terminators, polyadenylation sites, etc.), and a
selectable marker. Following the introduction of foreign DNA,
engineered cells may be allowed to grow for 1-2 days in an enriched
media, and then are switched to a selective media. The selectable
marker in the recombinant plasmid confers resistance to the
selection and allows cells to stably integrate the plasmid into
their chromosomes and grow to form foci which in turn can be cloned
and expanded into cell lines. This method may advantageously be
used to engineer cell lines which express an MKK.
[0069] A number of selection systems may be used, including but not
limited to the herpes simplex virus thymidine kinase (Wigler et
al., 1977, Cell 11:223), hypoxanthine-guanine
phosphoribosyltransferase (Szybalska & Szybalski, 1962, Proc.
Natl. Acad. Sci. USA 48:2026), and adenine
phosphoribosyltransferase (Lowy et al., 1980, Cell 22:817) genes
can be employed in tk-, hgprt- or aprt-cells, respectively. Also,
antimetabolite resistance can be used as the basis of selection for
dhfr, which confers resistance to methotrexate (Wigler et al.,
1980, Natl. Acad. Sci. USA 77:3567; O'Hare et al., 1981, Natl.
Acad. Sci. USA 78:1527); gpt, which confers resistance to
mycophenolic acid (Mulligan & Berg, 1981), Natl. Acad. Sci. USA
78:2072); neo, which confers resistance to the aminoglycoside G-418
(Colberre-Garapin et al., 1981, J. Mol. Biol. 150:1); and hygro,
which confers resistance to hygromycin (Santerre et al., 1984, Gene
30:147). Recently, additional selectable genes have been described,
namely trpB, which allows cells to utilize indole in place of
tryptophan; hisD, which allows cells to utilize histinol in place
of histidine (Hartman & Mulligan, 1988, Proc. Natl. Acad. Sci.
USA 85:8047); and ODC (ornithine decarboxylase) which confers
resistance to the omithine decarboxylase inhibitor,
2-(difluoromethyl)-DL-ornithine, DFMO (McConlogue L., 1987, In:
Current Communications in Molecular Biology, Cold Spring Harbor
Laboratory, Ed.).
Identification of Transfectants or Transformants that Express the
MKK
[0070] The host cells which contain the coding sequence and which
express the biologically active gene product may be identified by
at least four general approaches; (a) DNA-DNA or DNA-RNA
hybridization; (b) the presence or absence of "marker" gene
functions; (c) assessing the level of transcription as measured by
the expression of MKK mRNA transcripts in the host cell; and (d)
detection of the gene product as measured by immunoassay or by its
biological activity.
[0071] In the first approach, the presence of the MKK coding
sequence inserted in the expression vector can be detected by
DNA-DNA or DNA-RNA hybridization using probes comprising nucleotide
sequences that arehomologous to the MKK coding sequence,
respectively, or portions or derivatives thereof.
[0072] In the second approach, the recombinant expression
vector/host system can be identified and selected based upon the
presence or absence of certain "marker" gene functions (e.g.,
thymidine kinase activity, resistance to antibiotics, resistance to
methotrexate, transformation phenotype, occlusion body formation in
baculovirus, etc.). For example, if the MKK1 coding sequence is
inserted within a marker gene sequence of the vector, recombinant
cells containing the MKK1 coding sequence can be identified by the
absence of the marker gene function. Alternatively, a marker gene
can be placed in tandem with an MKK sequence under the control of
the same or different promoter used to control the expression of
the MKK coding sequence. Expression of the marker in response to
induction or selection indicates expression of the MKK coding
sequence.
[0073] In the third approach, transcriptional activity for an MKK
coding region can be assessed by hybridization assays. For example,
RNA can be isolated and analyzed by Northern blot using a probe
homologous to an MKK coding sequence or particular portions
thereof. Alternatively, total nucleic acids of the host cell may be
extracted and assayed for hybridization to such probes.
[0074] In the fourth approach, the expression of an MKK protein
product can be assessed immunologically, for example by Western
blots, immunoassays such as radioimmuno-precipitation,
enzyme-linked immunoassays and the like.
Uses of MKK and Engineered Cell Lines
[0075] Megakaryocytes, the progenitor cell for blood platelets, and
platelets are associated with disease states involving aberrant
proliferation or differentiation of such cells, such as acute
megakaryocytic leukemia, acute megakaryocytic myelosis and
thrombocytopenia. MKKs appear to play a role in the growth and
differentiation of megkaryocytes, therefore inhibitors of MKKs may
be used therapeutically for the treatment of diseases states
resulting from aberrant growth of megakaryocytes or platelets.
Alternatively, enhancers of MKKs may be used therapeutically to
stimulate the proliferation of megakaryocytes in such applications
as, for example, ex vivo culturing of megakaryocytes intended for
autologous cell therapy in individuals receiving chemotherapy or
other therapies which deplete megakaryocytes or platelets or in
treating thrombocytopenia caused by other conditions.
[0076] In an embodiment of the invention, an MKK and/or cell line
that expresses an MKK may be used to screen for antibodies,
peptides, or other molecules that act as agonists or antagonists of
MKK through modulation of signal transduction pathways. For
example, anti-MKK antibodies capable of neutralizing the activity
of MKK may be used to inhibit an MKK associated signal transduction
pathway. Such antibodies can act intracellularly utilizing the
techniques described in Marasco et al. (PNAS 90:7889-7893 (1993)
for example or through delivery by liposomes. Alternatively,
screening of organic or peptide libraries with recombinantly
expressed MKK protein or cell lines expressing MKK protein may be
useful for identification of therapeutic molecules that function by
modulating the kinase activity of MKK or its associated signal
transduction pathway. A therapeutic molecule may find application
in a disease state associated with megakaryocytes, such as acute
megakaryocytic leukemia, or alternatively, in nondisease
applications, for example in ex vivo culturing of megakaryocytes
intended for autologous treatment of individuals undergoing
chemotherapy. Synthetic compounds, natural products, and other
sources of potentially biologically active materials can be
screened in a number of ways deemed to be routine to those of skill
in the art.
[0077] The ability of antibodies, peptides, or other molecules to
prevent or mimic, the effect of MKK on signal transduction
responses on MKK expressing cells may be measured. For example,
responses such as activation or inhibition of MKK kinase activity
or modulation of second messenger production may be monitored. The
term "second messenger" as used herein refers to any component or
product found in the cascade of signal transduction events. These
assays may be performed using conventional techniques developed for
these purposes.
Antibody Production and Screening
[0078] Various procedures known in the art may be used for the
production of antibodies to epitopes of the recombinantly produced
MKK. Such antibodies include but are not limited to polyclonal,
monoclonal, chimeric, single chain, Fab fragments and fragments
produced by a Fab expression library. Neutralizing antibodies,
i.e., those which inhibit the biological activity, i.e., the kinase
activity, of an MY are especially preferred for diagnostics and
therapeutics.
[0079] For the production of antibodies, various host animals may
be immunized by injection with an MKK protein including but not
limited to rabbits, mice, rats, etc. Various adjuvants may be used
to increase the immunological response, depending on the host
species, including but not limited to Freund's (complete and
incomplete), mineral gels such as aluminum hydroxide, surface
active substances such as lysolecithin, pluronic polyols,
polyanions, peptides, oil emulsions, keyhole limpet hemocyanin,
dinitrophenol, and potentially useful human adjuvants such as BCG
(bacilli Calmette-Guerin) and Corynebacterium parvum.
[0080] Monoclonal antibodies to an MKK may be prepared by using any
technique which provides for the production of antibody molecules
by continuous cell lines in culture. These include but are not
limited to the hybridoma technique originally described by Koehler
and Milstein, (Nature, 1975, 256:495-497), the human B-cell
hybridoma technique (Kosbor et al., 1983, Immunology Today, 4:72;
Cote et al., 1983, Proc. Natl. Acad. Sci, 80:2026-2030) and the
EBV-hybridoma technique (Cole et al., 1985, Monoclonal Antibodies
and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). In addition,
techniques developed for the production of "chimeric antibodies"
(Morrison et al., 1984, Proc. Natl. Acad. Sci. 81:6851-6855;
Neuberger et al, 1984, Nature, 312:604-608; Takeda et al., 1985,
Nature 314:452-454) by splicing the genes from a mouse antibody
molecule of appropriate antigen specificity together with genes
from a human antibody molecule of appropriate biological activity
can be used. Alternatively, techniques described for the production
of single chain antibodies (U.S. Pat. No. 4,946,778) can be adapted
to produce an MKK-specific single chain antibodies.
[0081] Antibody fragments which contain specific binding sites of
an MKK may be generated by known techniques. For example, such
fragments include but are not limited to: the F(ab').sub.2
fragments which can be produced by pepsin digestion of the antibody
molecule and the Fab fragments which can be generated by reducing
the disulfide bridges of the F(ab').sub.2 fragments. Alternatively,
Fab expression libraries may be constructed (Huse et al., 1989,
Science 246:1275-1281) to allow rapid and easy identification of
monoclonal Fab fragments with the desired specificity the MKK of
interest.
Screening of Peptide Library with MKK or MKK Engineered Cell
Lines
[0082] Random peptide libraries consisting of all possible
combinations of amino acids attached to a solid phase support may
be used to identify peptides that are able to bind to MKK binding
sites, e.g., SH2, SH3 or PH binding sites, or other functional
domains of an MKK, such as kinase domains. The screening of peptide
libraries may have therapeutic value in the discovery of
pharmaceutical agents that act to stimulate or inhibit the
biological activity of an MKK.
[0083] Identification of molecules that are able to bind to an MKK
may be accomplished by screening a peptide library with recombinant
MKK protein. Methods for expression of an MKK are described in
Section 5.2, 5.3 and 5.4 and may be used to express a recombinant
full length MKK or fragments of an MKK depending on the functional
domains of interest. For example, the kinase and SH2, SH3 or PH
binding domains of an MKK may be separately expressed and used to
screen peptide libraries.
[0084] To identify and isolate the peptide/solid phase support that
interacts and forms a complex with an MKK, it is necessary to label
or "tag" the MKK molecule. The MKK protein may be conjugated to
enzymes such as alkaline phosphatase or horseradish peroxidase or
to other reagents such as fluorescent labels which may include
fluorescein isothyiocynate (FITC), phycoerythrin (PE) or rhodamine.
Conjugation of any given label to MKK may be performed using
techniques that are routine in the art. Alternatively, MKK
expression vectors may be engineered to express a chimeric MKK
protein containing an epitope for which a commercially available
antibody exists. The epitope specific antibody may be tagged using
methods well known in the art including labeling with enzymes,
fluorescent dyes or colored or magnetic beads.
[0085] The "tagged" MKK conjugate is incubated with the random
peptide library for 30 minutes to one hour at 22.degree. C. to
allow complex formation between an MKK and peptide species within
the library. The library is then washed to remove any unbound MKK
protein. If MKK has been conjugated to alkaline phosphatase or
horseradish peroxidase the whole library is poured into a petri
dish containing a substrates for either alkaline phosphatase or
peroxidase, for example, 5-bromo-4-chloro-3-indoyl phosphate (BCIP)
or 3,3',4,4''-diamnobenzidine (DAB), respectively. After incubating
for several minutes, the peptide/solid phase-MKK complex changes
color, and can be easily identified and isolated physically under a
dissecting microscope with a micromanipulator. If a fluorescent
tagged MKK molecule has been used, complexes may be isolated by
fluorescent activated sorting. If a chimeric MKK protein expressing
a heterologous epitope has been used, detection of the peptide/MKK
complex may be accomplished by using a labeled epitope specific
antibody. Once isolated, the identity of the peptide attached to
the solid phase support may be determined by peptide
sequencing.
Screening of Organic Compounds with MKK Protein or Engineered Cell
Lines
[0086] Cell lines that express an MKK may be used to screen for
molecules that modulate MKK activity or signal transduction. Such
molecules may include small organic or inorganic compounds or
extracts of biological materials such as plants, fungi, etc., or
other molecules that modulate MKK activity or that promote or
prevent MKK mediated signal transduction. Synthetic compounds,
natural products, and other sources of potentially biologically
active materials can be screened in a number of ways.
[0087] The ability of a test molecule to interfere with MKK signal
transduction may be measured using standard biochemical techniques.
Other responses such as activation or suppression of catalytic
activity, phosphorylation or dephosphorylation of other proteins,
activation or modulation of second messenger production, changes in
cellular ion levels, association, dissociation or translocation of
signalling molecules, or transcription or translation of specific
genes may also be monitored. These assays may be performed using
conventional techniques developed for these purposes in the course
of screening. (See, for example, Peralidi, et al., J. Biochem.
285:71-78 (1992) or Campbell et al., JBC 268:7427-7434 (1993)).
[0088] Cellular processes under the control of an MKK signalling
pathway may include, but are not limited to, normal cellular
functions such as proliferation or differentiation of
megakaryocytes or platelets, in addition to abnormal or potentially
deleterious processes such as unregulated or inappropriate
cellproliferation, blocking of differentiation of megakaryocytes or
platelets, or ultimately cell death. The qualitative or
quantitative observation and measurement of any of the described
cellular processes by techniques known in the art may be
advantageously used as a means of scoring for signal transduction
in the course of screening.
[0089] MKK, or functional derivatives thereof, useful in
identifying compounds capable of modulating signal transduction may
have, for example, amino acid deletions and/or insertions and/or
substitutions as long as they retain significant ability to
interact with some or all relevant components of a MKK signal
transduction pathway. A functional derivative of MKK may be
prepared from a naturally occurring or recombinantly expressed MKK
by proteolytic cleavage followed by conventional purification
procedures known to those skilled in the art. Alternatively, the
functional derivative may be produced by recombinant DNA technology
by expressing parts of MKK which include the functional domain in
suitable cells. Functional derivatives may also be chemically
synthesized. Cells expressing MKK may be used as a source of MKK,
crude or purified for testing in these assays.
[0090] MKK signal transduction activity may be measured by standard
biochemical techniques or by monitoring the cellular processes
controlled by the signal. To assess modulation of kinase activity,
the test molecule is added to a reaction mixture containing MKK and
a substrate. The kinase reaction is then initiated with the
addition of ATP. An immunoassay using an antiphosphotyrosine
antibody is performed on the kinase reaction to detect the presence
or absence of the phosphorylated tyrosine residues on the substrate
or to detect phosphorylated tyrosine residues on autophosphorylated
MKK, and results are compared to those obtained for controls i.e.,
reaction mixtures not exposed to the test molecule.
Uses of MKK Polynucleotide
[0091] An MKK polynucleotide may be used for diagnostic and/or
therapeutic purposes. For diagnostic purposes, an MKK
polynucleotide may be used to detect MKK gene expression or
aberrant MKK gene expression in disease states, e.g., acute
megakaryocytic leukemia or acute megakaryocytic myelosis. Included
in the scope of the invention are oligonucleotide sequences, that
include antisense RNA and DNA molecules and ribozymes, that
function to inhibit translation of an MKK. In a specific embodiment
of this aspect of the invention, an anti-MKK1 antisense molecule is
shown to inhibit MKK-1 protein synthesis resulting in reduced
megakaryocyte growth and differentiation.
Diagnostic Uses of an MKK Polynucleotide
[0092] An MKK polynucleotide may have a number of uses for the
diagnosis of diseases resulting from aberrant expression of MKK.
For example, the MKK1 DNA sequence may be used in hybridization
assays of biopsies or autopsies to diagnose abnormalities of MKK1
expression; e.g., Southern or Northern analysis, including in situ
hybridization assays. Such techniques are well known in the art,
and are in fact the basis of many commercially available diagnostic
kits.
Therapeutic Uses of an MKK Polynucleotide
[0093] An MKK polynucleotide may be useful in the treatment of
various abnormal conditions. By introducing gene sequences into
cells, gene therapy can be used to treat conditions in which the
cells do not proliferate or differentiate normally due to
underexpression of normal MKK or expression of abnormal/inactive
MKK. In some instances, the polynucleotide encoding an MKK is
intended to replace or act in the place of a functionally deficient
endogenous gene. Alternatively, abnormal conditions characterized
by overproliferation can be treated using the gene therapy
techniques described below.
[0094] Abnormal proliferation of megakaryocytis is an important
component of a variety of disease states such as acute
megakaryocytic leukemia, myelofibrosis, or acute megakaryocytic
myelosis. Recombinant genetherapy vectors, such as viral vectors,
may be engineered to express variant, signalling incompetent forms
of MKK which may be used to inhibit the activity of the naturally
occurring endogenous MKK. A signalling incompetent form may be, for
example, a truncated form of the protein that is lacking all or
part of its catalytic domain. Such a truncated form may participate
in normal binding to a substrate but lack enzymatic activity. Thus
recombinant gene therapy vectors may be used therapeutically for
treatment of diseases resulting from aberrant expression or
activity of an MKK. Accordingly, the invention provides a method of
inhibiting the effects of signal transduction by an endogenous MKK
protein in a cell comprising delivering a DNA molecule encoding a
signalling incompetent form of the MKK protein to the cell so that
the signalling incompetent MKK protein is produced in the cell and
competes with the endogenous MKK protein for access to molecules in
the MKK protein signalling pathway which activate or are activated
by the endogenous MKK protein.
[0095] Expression vectors derived from viruses such as
retroviruses, vaccinia virus, adeno-associated virus, herpes
viruses, or bovine papilloma virus, may be used for delivery of
recombinant MKK into the targeted cell population. Methods which
are well known to those skilled in the art can be used to construct
recombinant viral vectors containing an MKK polynucleotide
sequence. See, for example, the techniques described in Maniatis et
al., 1989, Molecular Cloning A Laboratory Manual, Cold Spring
Harbor Laboratory, N.Y. and Ausubel et al., 1989, Current Protocols
in Molecular Biology, Greene Publishing Associates and Wiley
Interscience, N.Y. Alternatively, recombinant MKK molecules can be
reconstituted into liposomes for delivery to target cells.
[0096] Oligonucleotide sequences, that include anti-sense RNA and
DNA molecules and ribozymes that function to inhibit the
translation of an MKK mRNA are within the scope of the invention.
Anti-sense RNA and DNA molecules act to directly block the
translation of mRNA by binding to targeted mRNA and preventing
protein translation. In regard to antisense DNA,
oligodeoxyribonucleotides derived from the translation initiation
site, e.g., between -10 and +10 regions of an MKK nucleotide
sequence, are preferred.
[0097] Ribozymes are enzymatic RNA molecules capable of catalyzing
the specific cleavage of RNA. The mechanism of ribozyme action
involves sequence specific hybridization of the ribozyme molecule
to complementary target RNA, followed by a endonucleolytic
cleavage. Within the scope of the invention are engineered
hammerhead motif ribozyme molecules that specifically and
efficiently catalyze endonucleolytic cleavage of MKK1 RNA
sequences.
[0098] Specific ribozyme cleavage sites within any potential RNA
target are initially identified by scanning the target molecule for
ribozyme cleavage sites which include the following sequences, GUA,
GUU and GUC. Once identified, short RNA sequences of between 15 and
20 ribonucleotides corresponding to the region of the target gene
containing the cleavage site may be evaluated for predicted
structural features such as secondary structure that may render the
oligonucleotide sequence unsuitable. The suitability of candidate
targets may also be evaluated by testing their accessibility to
hybridization with complementary oligonucleotides, using
ribonuclease protection assays.
[0099] Both anti-sense RNA and DNA molecules and ribozymes of the
invention may be prepared by any method known in the art for the
synthesis of RNA molecules. These include techniques for chemically
synthesizing oligodeoxyribonucleotides well known in the art such
as for example solid phase phosphoramidite chemical synthesis.
Alternatively, RNA molecules may be generated by in vitro and in
vivo transcription of DNA sequences encoding the antisense RNA
molecule. Such DNA sequences may be incorporated into a wide
variety of vectors which incorporate suitable RNA polymerase
promoters such as the T7 or SP6 polymerase promoters.
Alternatively, antisense cDNA constructs that synthesize antisense
RNA constitutively or inducibly, depending on the promoter used,
can be introduced stably into cell lines.
[0100] Various modifications to the DNA molecules may be introduced
as a means of increasing intracellular stability and half-life.
Possible modifications include but are not limited to the addition
of flanking sequences of ribo- or deoxy-nucleotides to the 5'
and/or 3'' ends of the molecule or the use of phosphorothioate or
2' O-methyl rather than phosphodiesterase linkages within the
oligodeoxyribonucleotide backbone.
[0101] Methods for introducing polynucleotides into such cells or
tissue include methods for in vitro introduction of polynucleotides
such as the insertion of naked polynucleotide, i.e., by injection
into tissue, the introduction of an MKK polynucleotide in a cell ex
vivo, i.e., for use in autologous cell therapy, the use of a vector
such as a virus, retrovirus, phage or plasmic, etc. or techniques
such as electroporation which may be used in vivo or ex vivo.
EXAMPLES
Cloning and Characterization of MKK1
[0102] For clarity of discussion, the subsection below describes
the isolation and characterization of a cDNA clone encoding the
novel tyrosine kinase designated MKK1. The MKK2 and MKK3 genes were
cloned and characterized using the same methods.
cDNA Cloning MKK Expression and MKK Characterization
[0103] Confluent plates of K-562 cells (ATCC accession number CCL
243) were lysed by treatment with guanidinium-thiocyanate according
to Chirgwin et al. (1979, Biochemistry 18:5294-5299). Total RNA was
isolated by CsC1-gradient centrifugation. First-strand cDNA was
synthesized from 20 .mu.g total RNA with avian myeloblastosis virus
(AMV) reverse transcriptase (Boehringer Mannheim).
[0104] cDNA was used in a polymerase chain reaction under standard
conditions (PCR Technology-Principles and Applications for DNA
Amplifications, H. E. Erlich, Ed., Stockton Press, New York 1989).
Degenerate pools of primers corresponding to the amino acid
sequence HRDLAA) residues 350-355 of SEQ ID NO: 2) and SDVWSF/Y
(SEQ ID NO: 24) were prepared and used for the amplification:
TABLE-US-00001 5' oligo pool H R D L A 5' GGAATTCC CAC AGN GAC TTN
GCN (SEQ ID NO: 20) T C A T C A A GCN AG 3' A C 3' oligo pool F/Y S
W V D 5' GGAATTCC GAA NGT CCA NAC GTC (SEQ ID NO: 21) ATG CA C S
NGA 3' C
Thirty-five PCR cycles were carried out using 8 .mu.g (0.8 .mu.g)
of the pooled primers. (Annealing 55.degree. C., 1 min; Extension
72.degree. C., 2 min; Denaturation 94.degree. C., 1 min). The
reaction product was subjected to polyacrylamide gel
electrophoresis. Fragments of the expected size (.about.210 bp)
were isolated, digested with the restriction enzyme EcoRI, and
subcloned into the pBluskript vector (Stratagene) using standard
techniques (Current Protocols in Molecular Biology, eds. F. M.
Ausubel et al., John Wiley & Sons, New York, 1988).
[0105] The recombinant plasmids were transformed into the competent
E. coli strain designated 298.
[0106] The subcloned PCR products were sequenced by the method of
Sanger et al. (Proc. Natl. Acad. Sci USA 74, 5463-5467) using
Sequenase (United States Biochemical, Cleveland, Ohio 44111 USA).
Clones designated MKK1, MKK2, and MKK3 were identified as novel
TKs.
Full-Length cDNA Cloning
[0107] The partial cDNA sequence of the new MKK1 TK, which was
identified by PCR, was used to screen a .lamda.gt11 library from
human fetal brain CDNA (Clontech) (complexity of 1.times.10.sup.10
recombinant phages). One million independent phage clones were
plated and transferred to nitrocellulose filters following standard
procedures (Sambrook, H. J., Molecular Cloning, Cold Spring Harbor
Laboratory Press, USA, 1989). The filters were hybridized to the
EcoRI/EcoRI fragment of clone MKK1, which had been radioactively
labeled using 50 .mu.Ci [.alpha..sup.32P]ATP and the random-primed
DNA labeling kit (Boehringer Mannheim). The longest eDNA insert of
.about.3500 by was digested with the restriction enzymes EcoRI/Sacd
to obtain a 5' end probe of 250 bp. This probe was used to rescreen
the human fetal brain library and several overlapping clones were
isolated. The composite of the cDNA clones of MKK1, MKK2 and MKK3
is shown in FIGS. 1A-1B (SEQ ID NOS 1-2), 2A-2B (SEQ ID NOS 3-4)
and 3A-3B (SEQ ID NOS 5-6), respectively. The 1.75 million
independent phage clones of a human placenta library, .lamda.ZAP,
were plated and screened with the 5' end probe (EcoRI/SacI) of the
clone used above. Subcloning of positive bacteriophages clones into
pBluskript vector was done by the in vivo excision protocol
(Stratagene).
[0108] The composite cDNA sequence and the predicted amino acid
sequence of MKK1, MKK2 and MKK3 are shown in FIGS. 1A-1B (SEQ ID
NOS 1-2), 2A-2B (SEQ ID NOS 3-4) and 3A-3B (SEQ ID NOS 5-6),
respectively.
MKK Expression
[0109] E.coli expression constructs for MKK1, MKK2 and MKK3 were
produced by cloning of the corresponding cDNA fragments into a
plasmid expression vector pTZS2 (Ray et al., PNAS USA
89:(13):5705-5709 (1992)) by substitution of recoverin coding
sequence with synthetic polylinker fragment. To provide in-frame
connection of the coding sequences to prokaryotic translation
initiation site coded by the vector, an NdeI restriction site
overlapping start codon (CATATG) was introduced in all three MKK
cDNAs by site directed mutagenesis. The resulting constructs are
designed to drive expression of unfused proteins with authentic
amino acid sequences. FIG. 8 shows MKK expression constructs.
RNA Blot Analysis of MKKs
[0110] Total RNA was isolated from human megakaryocytes, myeloid
cells, B-cells, T-cells, and epithelial cells.
[0111] PolyA.sup.+ RNA was isolated on an oligo (dT) column (Aviv
and Leder, 1972, Proc. Natl. Acad. Sci. USA 69, 1408-1412). The
poly A+ RNA was isolated using RNA stat-60 method (Tel-Test B Inc.)
and blotted on a nitrocellulose filter using a slot blot apparatus
(Schleicher and Schuell). 2 .mu.g of poly A.sup.+ RNA was loaded
per lane. The filter was hybridized with a .sup.32P-labeled
EcoRI/EcoRI DNA fragment obtained by PCR. Subsequently, the filter
was exposed to x-ray film at -70.degree. C. with an intensifying
screen. The results, as shown in FIG. 4, suggest that MKK1 and MKK2
are preferentially expressed in megakaryocytes. MKK3 expression
could not be detected using this technique. FIG. 8 shows MKK
expression constructs.
EXAMPLE
Autophosphorylation of MKK2 and MKK3
[0112] FIG. 7 represents Western blot analysis of protein from
bacteria expressing MKK1, MKK2, or MKK3 using an
anti-phosphotyrosine antibody (Hansen et al., Electrophoresis
14:112-126 (1993)). All MKK constructs were cloned into the
inducible vector pTZS2, and transformed bacteria were grown under
induced and uninduced conditions as described by Ray, et al., (PNAS
USA 89:5705-5709 (1992)). Bacterial pellets from these cultures
were resuspended in sample buffer, containing 2-mercaptoethanol and
SDS, and boiled. Proteins were separated by SDS-polyacrylamide gel
electrophoresis. The results of this example indicate that MKK2 and
MKK3 have kinase activity.
EXAMPLE
Production of Anti-MKK Antibodies and Immunoprecipitation of
MKK
[0113] Antibodies recognizing MKK1 and MKK2 protein were made in
rabbits using standard procedures. The anti-carboxy terminus MKK1
antibody was generated using the synthetic peptide GQDADGSTSPRSQEP
(SEQ ID NO 22). The amino-terminus MKK1 Ab was generated using a
GST-fusion proteins containing 78 amino acids coded by the Smal to
BG12 fragment of the MKK1 gene. The anti-carboxy terminus MKK2 Ab
was made using a synthetic peptide corresponding to the sequence
QQLLSSIEPLREKDKH (SEQ ID NO 23).
[0114] MKK1 and MKK2, cloned into the pBluskript plasmid, were
transcribed and translated in the presence of .sup.35S-methione
using standard methods. Following protein synthesis MKK1 and MKK2
were immunoprecipitated (i.p.) with the appropriate rabbit
antibodies (Ab) in the presence of SDS. FIG. 5 shows
immunoprecipitation of in vitro transcribed and translated MKK1 and
MKK2 proteins.
EXAMPLE
Expression of MKK1 Anti-Sense Sequences
[0115] Bone Marrow elements isolated from mice treated with
5-flurourocil 6 days prior to harvest were infected with
retroviruses containing constructs expressing MKK1, antisense MKK1
(a truncated 5' EcoRI-PvuII fragment cloned in the reverse
orientation) or the empty retroviral vector (mock). Following
infection, cells were cultured and analyzed for the level of
acetylcholinesterase (AChE) as previously described, measured as
optical density at 414 nm (Hill, Exp. Hematology 20:354-360 (1992).
A higher optical density reading indicates a greater AChE level and
correlates with increased megakaryocyte growth and differentiation.
Levels of the marine MKK1 protein were determined by metabolically
labeling cells with .sup.35S-methionine for 12 hours at the end of
the experimental period. Following labeling, cells were lysed and
MKK 1 protein was isolated by two cycles of immunoprecipitation
using anti-amino terminus MKK1 antibody. The proteins were resolved
by polyacrylamide gel electrophoresis and visualized by
autoradiography.
[0116] The retroviral construct used (PSR/MSV-Tkneo) was previously
described (Mol. Cell. Biol. 11:1785-1792 (1991)). The MKK1 sense
construct represents the full length gene lacking the
poly-adenylation sequences. The MKK1 antisense construct represents
the 5' fragment EcoRI-PvuII cloned in the reverse orientation. Both
the sense and antisense constructs are driven by the retroviral
long terminal repeat (LTR).
[0117] The results of the experiment, as shown in FIGS. 6A-6B,
indicate that expression of the MKK1 anti-sense sequences in the
cultured bone marrow elements is associated with decreased
expression of MKK1 and decreased levels of ACHE, an indicator of
megakaryocyte growth and differentiation.
[0118] Various modifications of the invention, in addition to those
shown and described herein, will become apparent to those skilled
in the art from the foregoing description. Such modifications are
intended to fall within the scope of the appended claims. It is
also to be understood that all base pair sizes given for
nucleotides are approximate and are used for purposes of
description.
[0119] All references cited herein are hereby incorporated by
reference in their entirety.
Sequence CWU 1
1
24 1 2000 DNA Unknown Organism CDS (258)..(1778) Description of
Unknown Organism Megakaryocyte kinase 1 1 ctcgctccaa gttgtgcagc
cgggaccgcc tcggggtgtg cagccggctc gcggaggccc 60 tcctgggggc
gggcgcgggg cggctcgggg gcgccccctg agcagaaaac aggaagaacc 120
aggctcggtc cagtggcacc cagctcccta cctcctgtgc cagccgcctg gcctgtggca
180 ggccattccc agcgtccccg actgtgacca cttgctcagt gtgcctctca
cctgcctcag 240 tttccctctg gggggcg atg gcg ggg cga ggc tct ctg gtt
tcc tgg cgg 290 Met Ala Gly Arg Gly Ser Leu Val Ser Trp Arg 1 5 10
gca ttt cac ggc tgt gat tct gct gag gaa ctt ccc cgg gtg agc ccc 338
Ala Phe His Gly Cys Asp Ser Ala Glu Glu Leu Pro Arg Val Ser Pro 15
20 25 cgc ttc ctc cga gcc tgg cac ccc cct ccc gtc tca gcc agg atg
cca 386 Arg Phe Leu Arg Ala Trp His Pro Pro Pro Val Ser Ala Arg Met
Pro 30 35 40 acg agg cgc tgg gcc ccg ggc acc cag tgt atc acc aaa
tgc gag cac 434 Thr Arg Arg Trp Ala Pro Gly Thr Gln Cys Ile Thr Lys
Cys Glu His 45 50 55 acc cgc ccc aag cca ggg gag ctg gcc ttc cgc
aag ggc gac gtg gtc 482 Thr Arg Pro Lys Pro Gly Glu Leu Ala Phe Arg
Lys Gly Asp Val Val 60 65 70 75 acc atc ctg gag gcc tgc gag aac aag
agc tgg tac cgc gtc aag cac 530 Thr Ile Leu Glu Ala Cys Glu Asn Lys
Ser Trp Tyr Arg Val Lys His 80 85 90 cac acc agt gga cag gag ggg
ctg ctg gca gct ggg gcg ctg cgg gag 578 His Thr Ser Gly Gln Glu Gly
Leu Leu Ala Ala Gly Ala Leu Arg Glu 95 100 105 cgg gag gcc ctc tcc
gca gac ccc aag ctc agc ctc atg ccg tgg ttc 626 Arg Glu Ala Leu Ser
Ala Asp Pro Lys Leu Ser Leu Met Pro Trp Phe 110 115 120 cac ggg aag
atc tcg ggc cag gag gct gtc cag cag ctg cag cct ccc 674 His Gly Lys
Ile Ser Gly Gln Glu Ala Val Gln Gln Leu Gln Pro Pro 125 130 135 gag
gat ggg ctg ttc ctg gtg cgg gag tcc gcg cgc cac ccc ggc gac 722 Glu
Asp Gly Leu Phe Leu Val Arg Glu Ser Ala Arg His Pro Gly Asp 140 145
150 155 tac gtc ctg tgc gtg agc ttt ggc cgc gac gtc atc cac tac cgc
gtg 770 Tyr Val Leu Cys Val Ser Phe Gly Arg Asp Val Ile His Tyr Arg
Val 160 165 170 ctg cac cgc gac ggc cac ctc aca atc gat gag gcc gtg
ttc ttc tgc 818 Leu His Arg Asp Gly His Leu Thr Ile Asp Glu Ala Val
Phe Phe Cys 175 180 185 aac ctc atg gac atg gtg gag cat tac agc aag
gac aag ggc gct atc 866 Asn Leu Met Asp Met Val Glu His Tyr Ser Lys
Asp Lys Gly Ala Ile 190 195 200 tgc acc aag ctg gtg aga cca aag cgg
aaa cac ggg acc aag tcg gcc 914 Cys Thr Lys Leu Val Arg Pro Lys Arg
Lys His Gly Thr Lys Ser Ala 205 210 215 gag gag gag ctg gcc agg gcg
ggc tgg tta ctg aac ctg cag cat ttg 962 Glu Glu Glu Leu Ala Arg Ala
Gly Trp Leu Leu Asn Leu Gln His Leu 220 225 230 235 aca ttg gga gca
cag atc gga gag gga gag ttt gga gct gtc ctg cag 1010 Thr Leu Gly
Ala Gln Ile Gly Glu Gly Glu Phe Gly Ala Val Leu Gln 240 245 250 ggt
gag tac ctg ggg caa aag gtg gcc gtg aag aat atc aag tgt gat 1058
Gly Glu Tyr Leu Gly Gln Lys Val Ala Val Lys Asn Ile Lys Cys Asp 255
260 265 gtg aca gcc cag gcc ttc ctg gac gag acg gcc gtc atg acg aag
atg 1106 Val Thr Ala Gln Ala Phe Leu Asp Glu Thr Ala Val Met Thr
Lys Met 270 275 280 caa cac gag aac ctg gtg cgt ctc ctg ggc gtg atc
ctg cac cag ggg 1154 Gln His Glu Asn Leu Val Arg Leu Leu Gly Val
Ile Leu His Gln Gly 285 290 295 ctg tac att gtc atg gag cac gtg agc
aag ggc aac ctg gtg aac ttt 1202 Leu Tyr Ile Val Met Glu His Val
Ser Lys Gly Asn Leu Val Asn Phe 300 305 310 315 ctg cgg acc cgg ggt
cga gcc ctc gtg aac acc gct cag ctc ctg cag 1250 Leu Arg Thr Arg
Gly Arg Ala Leu Val Asn Thr Ala Gln Leu Leu Gln 320 325 330 ttt tct
ctg cac gtg gcc gag ggc atg gag tac ctg gag agc aag aag 1298 Phe
Ser Leu His Val Ala Glu Gly Met Glu Tyr Leu Glu Ser Lys Lys 335 340
345 ctt gtg cac cgc gac ctg gcc gcc cgc aac atc ctg gtc tca gag gac
1346 Leu Val His Arg Asp Leu Ala Ala Arg Asn Ile Leu Val Ser Glu
Asp 350 355 360 ctg gtg gcc aag gtc agc gac ttt ggc ctg gcc aaa gcc
gag cgg aag 1394 Leu Val Ala Lys Val Ser Asp Phe Gly Leu Ala Lys
Ala Glu Arg Lys 365 370 375 ggg cta gac tca agc cgg ctg ccc gtc aag
tgg acg gcg ccc gag gct 1442 Gly Leu Asp Ser Ser Arg Leu Pro Val
Lys Trp Thr Ala Pro Glu Ala 380 385 390 395 ctc aaa cac ggg aag ttc
acc agc aag tcg gat gtc tgg agt ttt ggg 1490 Leu Lys His Gly Lys
Phe Thr Ser Lys Ser Asp Val Trp Ser Phe Gly 400 405 410 gtg ctg ctc
tgg gag gtc ttc tca tat gga cgg gct ccg tac cct aaa 1538 Val Leu
Leu Trp Glu Val Phe Ser Tyr Gly Arg Ala Pro Tyr Pro Lys 415 420 425
atg tca ctg aaa gag gtg tcg gag gcc gtg gag aag ggg tac cgc atg
1586 Met Ser Leu Lys Glu Val Ser Glu Ala Val Glu Lys Gly Tyr Arg
Met 430 435 440 gaa ccc ccc gag ggc tgt cca ggc ccc gtg cac gtc ctc
atg agc agc 1634 Glu Pro Pro Glu Gly Cys Pro Gly Pro Val His Val
Leu Met Ser Ser 445 450 455 tgc tgg gag gca gag ccc gcc cgc cgg cca
ccc ttc cgc aaa ctg gcc 1682 Cys Trp Glu Ala Glu Pro Ala Arg Arg
Pro Pro Phe Arg Lys Leu Ala 460 465 470 475 gag aag ctg gcc cgg gag
cta cgc agt gca ggt gcc cca gcc tcc gtc 1730 Glu Lys Leu Ala Arg
Glu Leu Arg Ser Ala Gly Ala Pro Ala Ser Val 480 485 490 tca ggg cag
gac gcc gac ggc tcc acc tcg ccc cga agc cag gag ccc 1778 Ser Gly
Gln Asp Ala Asp Gly Ser Thr Ser Pro Arg Ser Gln Glu Pro 495 500 505
tgaccccacc cggtggggcc cttggcccca gaggaccgag agagtggaga gtgcggcgtg
1838 ggggcactga ccaggcccaa ggagggtcca ggcgggcaag tcatcctcct
ggtgcccaca 1898 gcaggggctg gcccacgtag ggggctctgg gcggcccgtg
gacaccccag acctgcgaag 1958 gatgatcgcc cgataaagac ggattctaag
gactctaaaa aa 2000 2 507 PRT Unknown Organism Description of
Unknown Organism Megakaryocyte kinase 1 2 Met Ala Gly Arg Gly Ser
Leu Val Ser Trp Arg Ala Phe His Gly Cys 1 5 10 15 Asp Ser Ala Glu
Glu Leu Pro Arg Val Ser Pro Arg Phe Leu Arg Ala 20 25 30 Trp His
Pro Pro Pro Val Ser Ala Arg Met Pro Thr Arg Arg Trp Ala 35 40 45
Pro Gly Thr Gln Cys Ile Thr Lys Cys Glu His Thr Arg Pro Lys Pro 50
55 60 Gly Glu Leu Ala Phe Arg Lys Gly Asp Val Val Thr Ile Leu Glu
Ala 65 70 75 80 Cys Glu Asn Lys Ser Trp Tyr Arg Val Lys His His Thr
Ser Gly Gln 85 90 95 Glu Gly Leu Leu Ala Ala Gly Ala Leu Arg Glu
Arg Glu Ala Leu Ser 100 105 110 Ala Asp Pro Lys Leu Ser Leu Met Pro
Trp Phe His Gly Lys Ile Ser 115 120 125 Gly Gln Glu Ala Val Gln Gln
Leu Gln Pro Pro Glu Asp Gly Leu Phe 130 135 140 Leu Val Arg Glu Ser
Ala Arg His Pro Gly Asp Tyr Val Leu Cys Val 145 150 155 160 Ser Phe
Gly Arg Asp Val Ile His Tyr Arg Val Leu His Arg Asp Gly 165 170 175
His Leu Thr Ile Asp Glu Ala Val Phe Phe Cys Asn Leu Met Asp Met 180
185 190 Val Glu His Tyr Ser Lys Asp Lys Gly Ala Ile Cys Thr Lys Leu
Val 195 200 205 Arg Pro Lys Arg Lys His Gly Thr Lys Ser Ala Glu Glu
Glu Leu Ala 210 215 220 Arg Ala Gly Trp Leu Leu Asn Leu Gln His Leu
Thr Leu Gly Ala Gln 225 230 235 240 Ile Gly Glu Gly Glu Phe Gly Ala
Val Leu Gln Gly Glu Tyr Leu Gly 245 250 255 Gln Lys Val Ala Val Lys
Asn Ile Lys Cys Asp Val Thr Ala Gln Ala 260 265 270 Phe Leu Asp Glu
Thr Ala Val Met Thr Lys Met Gln His Glu Asn Leu 275 280 285 Val Arg
Leu Leu Gly Val Ile Leu His Gln Gly Leu Tyr Ile Val Met 290 295 300
Glu His Val Ser Lys Gly Asn Leu Val Asn Phe Leu Arg Thr Arg Gly 305
310 315 320 Arg Ala Leu Val Asn Thr Ala Gln Leu Leu Gln Phe Ser Leu
His Val 325 330 335 Ala Glu Gly Met Glu Tyr Leu Glu Ser Lys Lys Leu
Val His Arg Asp 340 345 350 Leu Ala Ala Arg Asn Ile Leu Val Ser Glu
Asp Leu Val Ala Lys Val 355 360 365 Ser Asp Phe Gly Leu Ala Lys Ala
Glu Arg Lys Gly Leu Asp Ser Ser 370 375 380 Arg Leu Pro Val Lys Trp
Thr Ala Pro Glu Ala Leu Lys His Gly Lys 385 390 395 400 Phe Thr Ser
Lys Ser Asp Val Trp Ser Phe Gly Val Leu Leu Trp Glu 405 410 415 Val
Phe Ser Tyr Gly Arg Ala Pro Tyr Pro Lys Met Ser Leu Lys Glu 420 425
430 Val Ser Glu Ala Val Glu Lys Gly Tyr Arg Met Glu Pro Pro Glu Gly
435 440 445 Cys Pro Gly Pro Val His Val Leu Met Ser Ser Cys Trp Glu
Ala Glu 450 455 460 Pro Ala Arg Arg Pro Pro Phe Arg Lys Leu Ala Glu
Lys Leu Ala Arg 465 470 475 480 Glu Leu Arg Ser Ala Gly Ala Pro Ala
Ser Val Ser Gly Gln Asp Ala 485 490 495 Asp Gly Ser Thr Ser Pro Arg
Ser Gln Glu Pro 500 505 3 2500 DNA Unknown Organism CDS
(82)..(2106) Description of Unknown Organism Megakaryocyte kinase 2
3 ccgctttttg cttagagctt gagagtcaaa gttaaggacc cacatgtata cttcggctct
60 agcgagtcta aggatgataa t atg gat aca aaa tct att cta gaa gaa ctt
111 Met Asp Thr Lys Ser Ile Leu Glu Glu Leu 1 5 10 ctt ctc aaa aga
tca cag caa aag aag aaa atg tca cca aat aat tac 159 Leu Leu Lys Arg
Ser Gln Gln Lys Lys Lys Met Ser Pro Asn Asn Tyr 15 20 25 aaa gaa
cgg ctt ttt gtt ttg acc aaa aca aac ctt tcc tac tat gaa 207 Lys Glu
Arg Leu Phe Val Leu Thr Lys Thr Asn Leu Ser Tyr Tyr Glu 30 35 40
tat gac aaa atg aaa agg ggc agc aga aaa gga tcc att gaa att aag 255
Tyr Asp Lys Met Lys Arg Gly Ser Arg Lys Gly Ser Ile Glu Ile Lys 45
50 55 aaa atc aga tgt gtg gag aaa gta aat ctc gag gag cag acg cct
gta 303 Lys Ile Arg Cys Val Glu Lys Val Asn Leu Glu Glu Gln Thr Pro
Val 60 65 70 gag aga cag tac cca ttt cag att gtc tat aaa gat ggg
ctt ctc tat 351 Glu Arg Gln Tyr Pro Phe Gln Ile Val Tyr Lys Asp Gly
Leu Leu Tyr 75 80 85 90 gtc tat gca tca aat gaa gag agc cga agt cag
tgg ttg aaa gca tta 399 Val Tyr Ala Ser Asn Glu Glu Ser Arg Ser Gln
Trp Leu Lys Ala Leu 95 100 105 caa aaa gag ata agg ggt aac ccc cac
ctg ctg gtc aag tac cat agt 447 Gln Lys Glu Ile Arg Gly Asn Pro His
Leu Leu Val Lys Tyr His Ser 110 115 120 ggg ttc ttc gtg gac ggg aag
ttc ctg tgt tgc cag cag agc tgt aaa 495 Gly Phe Phe Val Asp Gly Lys
Phe Leu Cys Cys Gln Gln Ser Cys Lys 125 130 135 gca gcc cca gga tgt
acc ctc tgg gaa gca tat gct aat ctg cat act 543 Ala Ala Pro Gly Cys
Thr Leu Trp Glu Ala Tyr Ala Asn Leu His Thr 140 145 150 gca gtc aat
gaa gag aaa cac aga gtt ccc acc ttc cca gac aga gtg 591 Ala Val Asn
Glu Glu Lys His Arg Val Pro Thr Phe Pro Asp Arg Val 155 160 165 170
ctg aag ata cct cgg gca gtt cct gtt ctc aaa atg gat gca cca tct 639
Leu Lys Ile Pro Arg Ala Val Pro Val Leu Lys Met Asp Ala Pro Ser 175
180 185 tca agt acc act cta gcc caa tat gac aac gaa tca aag aaa aac
tat 687 Ser Ser Thr Thr Leu Ala Gln Tyr Asp Asn Glu Ser Lys Lys Asn
Tyr 190 195 200 ggc tcc cag cca cca tct tca agt acc agt cta gcg caa
tat gac agc 735 Gly Ser Gln Pro Pro Ser Ser Ser Thr Ser Leu Ala Gln
Tyr Asp Ser 205 210 215 aac tca aag aaa atc tat ggc tcc cag cca aac
ttc aac atg cag tat 783 Asn Ser Lys Lys Ile Tyr Gly Ser Gln Pro Asn
Phe Asn Met Gln Tyr 220 225 230 att cca agg gaa gac ttc cct gac tgg
tgg caa gta aga aaa ctg aaa 831 Ile Pro Arg Glu Asp Phe Pro Asp Trp
Trp Gln Val Arg Lys Leu Lys 235 240 245 250 agt agc agc agc agt gaa
gat gtt gca agc agt aac caa aaa gaa aga 879 Ser Ser Ser Ser Ser Glu
Asp Val Ala Ser Ser Asn Gln Lys Glu Arg 255 260 265 aat gtg aat cac
acc acc tca aag att tca tgg gaa ttc cct gag tca 927 Asn Val Asn His
Thr Thr Ser Lys Ile Ser Trp Glu Phe Pro Glu Ser 270 275 280 agt tca
tct gaa gaa gag gaa aac ctg gat gat tat gac tgg ttt gct 975 Ser Ser
Ser Glu Glu Glu Glu Asn Leu Asp Asp Tyr Asp Trp Phe Ala 285 290 295
ggt aac atc tcc aga tca caa tct gaa cag tta ctc aga caa aag gga
1023 Gly Asn Ile Ser Arg Ser Gln Ser Glu Gln Leu Leu Arg Gln Lys
Gly 300 305 310 aaa gaa gga gca ttt atg gtt aga aat tcg agc caa gtg
gga atg tac 1071 Lys Glu Gly Ala Phe Met Val Arg Asn Ser Ser Gln
Val Gly Met Tyr 315 320 325 330 aca gtg tcc tta ttt agt aag gct gtg
aat gat aaa aaa gga act gtc 1119 Thr Val Ser Leu Phe Ser Lys Ala
Val Asn Asp Lys Lys Gly Thr Val 335 340 345 aaa cat tac cac gtg cat
aca aat gct gag aac aaa tta tac ctg gca 1167 Lys His Tyr His Val
His Thr Asn Ala Glu Asn Lys Leu Tyr Leu Ala 350 355 360 gaa aac tac
tgt ttt gat tcc att cca aag ctt att cat tat cat caa 1215 Glu Asn
Tyr Cys Phe Asp Ser Ile Pro Lys Leu Ile His Tyr His Gln 365 370 375
cac aat tca gca ggc atg atc aca cgg ctc cgc cac cct gtg tca aca
1263 His Asn Ser Ala Gly Met Ile Thr Arg Leu Arg His Pro Val Ser
Thr 380 385 390 aag gcc aac aag gtc ccc gac tct gtg tcc ctg gga aat
gga atc tgg 1311 Lys Ala Asn Lys Val Pro Asp Ser Val Ser Leu Gly
Asn Gly Ile Trp 395 400 405 410 gaa ctg aaa aga gaa gag att acc ttg
ttg aag gag ctg gga agt ggc 1359 Glu Leu Lys Arg Glu Glu Ile Thr
Leu Leu Lys Glu Leu Gly Ser Gly 415 420 425 cag ttt gga gtg gtc cag
ctg ggc aag tgg aag ggg cag tat gat gtt 1407 Gln Phe Gly Val Val
Gln Leu Gly Lys Trp Lys Gly Gln Tyr Asp Val 430 435 440 gct gtt aag
atg atc aag gag ggc tcc atg tca gaa gat gaa ttc ttt 1455 Ala Val
Lys Met Ile Lys Glu Gly Ser Met Ser Glu Asp Glu Phe Phe 445 450 455
cag gag gcc cag act atg atg aaa ctc agc cat ccc aag ctg gtt aaa
1503 Gln Glu Ala Gln Thr Met Met Lys Leu Ser His Pro Lys Leu Val
Lys 460 465 470 ttc tat gga gtg tgt tca aag gaa tac ccc ata tac ata
gtg act gaa 1551 Phe Tyr Gly Val Cys Ser Lys Glu Tyr Pro Ile Tyr
Ile Val Thr Glu 475 480 485 490 tat ata agc aat ggc tgc ttg ctg aat
tac ctg agg agt cac gga aaa 1599 Tyr Ile Ser Asn Gly Cys Leu Leu
Asn Tyr Leu Arg Ser His Gly Lys 495 500 505 gga ctt gaa cct tcc cag
ctc tta gaa atg tgc tac gat gtc tgt gaa 1647 Gly Leu Glu Pro Ser
Gln Leu Leu Glu Met Cys Tyr Asp Val Cys Glu 510 515 520 ggc atg gcc
ttc ttg gag agt cac caa ttc ata cac cgg gac ttg gct 1695 Gly Met
Ala Phe Leu Glu Ser His Gln Phe Ile His Arg Asp Leu Ala 525 530 535
gct cgt aac tgc ttg gtg gac aga gat ctc tgt gtg aaa gta tct gac
1743 Ala Arg Asn Cys Leu Val Asp Arg Asp Leu Cys Val Lys Val Ser
Asp 540 545 550 ttt gga atg aca agg tat gtt ctt gat gac cag tat gtc
agt tca gtc 1791 Phe Gly Met Thr Arg Tyr Val Leu Asp Asp Gln Tyr
Val Ser Ser Val 555 560 565 570 gga aca aag ttt cca gtc aag tgg tca
gct cca gag gtg ttt cat tac 1839 Gly Thr Lys Phe Pro Val Lys Trp
Ser Ala Pro Glu Val Phe His Tyr 575 580 585 ttc aaa tac agc agc aag
tca gac gta tgg gca ttt ggg atc ctg atg 1887 Phe Lys Tyr Ser Ser
Lys Ser Asp Val Trp Ala Phe Gly Ile Leu Met 590 595 600 tgg gag gtg
ttc agc ctg ggg aag cag ccc tat gac ttg tat
gac aac 1935 Trp Glu Val Phe Ser Leu Gly Lys Gln Pro Tyr Asp Leu
Tyr Asp Asn 605 610 615 tcc cag gtg gtt ctg aag gtc tcc cag ggc cac
agg ctt tac cgg ccc 1983 Ser Gln Val Val Leu Lys Val Ser Gln Gly
His Arg Leu Tyr Arg Pro 620 625 630 cac ctg gca tcg gac acc atc tac
cag atc atg tac agc tgc tgg cac 2031 His Leu Ala Ser Asp Thr Ile
Tyr Gln Ile Met Tyr Ser Cys Trp His 635 640 645 650 gag ctt cca gaa
aag cgt ccc aca ttt cag caa ctc ctg tct tcc att 2079 Glu Leu Pro
Glu Lys Arg Pro Thr Phe Gln Gln Leu Leu Ser Ser Ile 655 660 665 gaa
cca ctt cgg gaa aaa gac aag cat tgaagaagaa attaggagtg 2126 Glu Pro
Leu Arg Glu Lys Asp Lys His 670 675 ctgataagaa tgaatataga
tgctggccag cattttcatt cattttaagg aaagtagcaa 2186 ggcataatgt
aatttagcta gtttttaata gtgttctctg tattgtctat tatttagaaa 2246
tgaacaaggc aggaaacaaa agattccctt gaaatttagg tcaaattagt aattttgttt
2306 atgctgcccc tgatataaca ctttccagcc tatagcagaa gcacattttc
agactgcaat 2366 atagagactg tgttcatgtg taaagactga gcagaactga
aaaattactt attggatatt 2426 cattcttttc tttatattgt cattgtcaca
acaattaaat atactaccaa gtacaaaaaa 2486 aaaaaaaaaa aaaa 2500 4 675
PRT Unknown Organism Description of Unknown Organism Megakaryocyte
kinase 2 4 Met Asp Thr Lys Ser Ile Leu Glu Glu Leu Leu Leu Lys Arg
Ser Gln 1 5 10 15 Gln Lys Lys Lys Met Ser Pro Asn Asn Tyr Lys Glu
Arg Leu Phe Val 20 25 30 Leu Thr Lys Thr Asn Leu Ser Tyr Tyr Glu
Tyr Asp Lys Met Lys Arg 35 40 45 Gly Ser Arg Lys Gly Ser Ile Glu
Ile Lys Lys Ile Arg Cys Val Glu 50 55 60 Lys Val Asn Leu Glu Glu
Gln Thr Pro Val Glu Arg Gln Tyr Pro Phe 65 70 75 80 Gln Ile Val Tyr
Lys Asp Gly Leu Leu Tyr Val Tyr Ala Ser Asn Glu 85 90 95 Glu Ser
Arg Ser Gln Trp Leu Lys Ala Leu Gln Lys Glu Ile Arg Gly 100 105 110
Asn Pro His Leu Leu Val Lys Tyr His Ser Gly Phe Phe Val Asp Gly 115
120 125 Lys Phe Leu Cys Cys Gln Gln Ser Cys Lys Ala Ala Pro Gly Cys
Thr 130 135 140 Leu Trp Glu Ala Tyr Ala Asn Leu His Thr Ala Val Asn
Glu Glu Lys 145 150 155 160 His Arg Val Pro Thr Phe Pro Asp Arg Val
Leu Lys Ile Pro Arg Ala 165 170 175 Val Pro Val Leu Lys Met Asp Ala
Pro Ser Ser Ser Thr Thr Leu Ala 180 185 190 Gln Tyr Asp Asn Glu Ser
Lys Lys Asn Tyr Gly Ser Gln Pro Pro Ser 195 200 205 Ser Ser Thr Ser
Leu Ala Gln Tyr Asp Ser Asn Ser Lys Lys Ile Tyr 210 215 220 Gly Ser
Gln Pro Asn Phe Asn Met Gln Tyr Ile Pro Arg Glu Asp Phe 225 230 235
240 Pro Asp Trp Trp Gln Val Arg Lys Leu Lys Ser Ser Ser Ser Ser Glu
245 250 255 Asp Val Ala Ser Ser Asn Gln Lys Glu Arg Asn Val Asn His
Thr Thr 260 265 270 Ser Lys Ile Ser Trp Glu Phe Pro Glu Ser Ser Ser
Ser Glu Glu Glu 275 280 285 Glu Asn Leu Asp Asp Tyr Asp Trp Phe Ala
Gly Asn Ile Ser Arg Ser 290 295 300 Gln Ser Glu Gln Leu Leu Arg Gln
Lys Gly Lys Glu Gly Ala Phe Met 305 310 315 320 Val Arg Asn Ser Ser
Gln Val Gly Met Tyr Thr Val Ser Leu Phe Ser 325 330 335 Lys Ala Val
Asn Asp Lys Lys Gly Thr Val Lys His Tyr His Val His 340 345 350 Thr
Asn Ala Glu Asn Lys Leu Tyr Leu Ala Glu Asn Tyr Cys Phe Asp 355 360
365 Ser Ile Pro Lys Leu Ile His Tyr His Gln His Asn Ser Ala Gly Met
370 375 380 Ile Thr Arg Leu Arg His Pro Val Ser Thr Lys Ala Asn Lys
Val Pro 385 390 395 400 Asp Ser Val Ser Leu Gly Asn Gly Ile Trp Glu
Leu Lys Arg Glu Glu 405 410 415 Ile Thr Leu Leu Lys Glu Leu Gly Ser
Gly Gln Phe Gly Val Val Gln 420 425 430 Leu Gly Lys Trp Lys Gly Gln
Tyr Asp Val Ala Val Lys Met Ile Lys 435 440 445 Glu Gly Ser Met Ser
Glu Asp Glu Phe Phe Gln Glu Ala Gln Thr Met 450 455 460 Met Lys Leu
Ser His Pro Lys Leu Val Lys Phe Tyr Gly Val Cys Ser 465 470 475 480
Lys Glu Tyr Pro Ile Tyr Ile Val Thr Glu Tyr Ile Ser Asn Gly Cys 485
490 495 Leu Leu Asn Tyr Leu Arg Ser His Gly Lys Gly Leu Glu Pro Ser
Gln 500 505 510 Leu Leu Glu Met Cys Tyr Asp Val Cys Glu Gly Met Ala
Phe Leu Glu 515 520 525 Ser His Gln Phe Ile His Arg Asp Leu Ala Ala
Arg Asn Cys Leu Val 530 535 540 Asp Arg Asp Leu Cys Val Lys Val Ser
Asp Phe Gly Met Thr Arg Tyr 545 550 555 560 Val Leu Asp Asp Gln Tyr
Val Ser Ser Val Gly Thr Lys Phe Pro Val 565 570 575 Lys Trp Ser Ala
Pro Glu Val Phe His Tyr Phe Lys Tyr Ser Ser Lys 580 585 590 Ser Asp
Val Trp Ala Phe Gly Ile Leu Met Trp Glu Val Phe Ser Leu 595 600 605
Gly Lys Gln Pro Tyr Asp Leu Tyr Asp Asn Ser Gln Val Val Leu Lys 610
615 620 Val Ser Gln Gly His Arg Leu Tyr Arg Pro His Leu Ala Ser Asp
Thr 625 630 635 640 Ile Tyr Gln Ile Met Tyr Ser Cys Trp His Glu Leu
Pro Glu Lys Arg 645 650 655 Pro Thr Phe Gln Gln Leu Leu Ser Ser Ile
Glu Pro Leu Arg Glu Lys 660 665 670 Asp Lys His 675 5 2770 DNA
Unknown Organism CDS (366)..(1880) Description of Unknown Organism
Megakaryocyte kinase 3 5 ccggactggt cgaaagacag gaacagactt
gaaacagggg gagagctcct ggcgaaacga 60 agacgtggag gttttaccag
ggataagaag aaaagacacc ttcctagtga gcagctgccc 120 agctcctgct
cagttttgcc tcggggtagc acctccagcc acagaaagca agccggtaag 180
tctctccagg taggacttgc tgcaacccag ctgctggact gatctgaaac gggactttgc
240 atactctccg aagtatggtg agttggtgct gacttcaaag ttgcctggtg
aaggaagata 300 aggtggatcg cagagactaa ggggagaggg agaagccctg
ctcctcttct ccccaccaag 360 gcaca atg agc aac atc tgt cag agg ctc tgg
gag tac cta gaa ccc tat 410 Met Ser Asn Ile Cys Gln Arg Leu Trp Glu
Tyr Leu Glu Pro Tyr 1 5 10 15 ctc ccc tgt ttg tcc acg gag gca gac
aag tca acc gtg att gaa aat 458 Leu Pro Cys Leu Ser Thr Glu Ala Asp
Lys Ser Thr Val Ile Glu Asn 20 25 30 cca ggg gcc ctt tgc tct ccc
cag tca cag agg cat ggc cac tac ttt 506 Pro Gly Ala Leu Cys Ser Pro
Gln Ser Gln Arg His Gly His Tyr Phe 35 40 45 gtg gct ttg ttt gat
tac cag gct cgg act gct gag gac ttg agc ttc 554 Val Ala Leu Phe Asp
Tyr Gln Ala Arg Thr Ala Glu Asp Leu Ser Phe 50 55 60 cga gca ggt
gac aaa ctt caa gtt ctg gac act ttg cat gag ggc tgg 602 Arg Ala Gly
Asp Lys Leu Gln Val Leu Asp Thr Leu His Glu Gly Trp 65 70 75 tgg
ttt gcc aga cac ttg gag aaa aga cga gat ggc tcc agt cag caa 650 Trp
Phe Ala Arg His Leu Glu Lys Arg Arg Asp Gly Ser Ser Gln Gln 80 85
90 95 cta caa ggc tat att cct tct aac tac gtg gct gag gac aga agc
cta 698 Leu Gln Gly Tyr Ile Pro Ser Asn Tyr Val Ala Glu Asp Arg Ser
Leu 100 105 110 cag gca gag ccg tgg ttc ttt gga gca atc gga aga tca
gat gca gag 746 Gln Ala Glu Pro Trp Phe Phe Gly Ala Ile Gly Arg Ser
Asp Ala Glu 115 120 125 aaa caa cta tta tat tca gaa aac aag acc ggt
tcc ttt cta atc aga 794 Lys Gln Leu Leu Tyr Ser Glu Asn Lys Thr Gly
Ser Phe Leu Ile Arg 130 135 140 gaa agt gaa agc caa aaa gga gaa ttc
tct ctt tca gtt tta gat gga 842 Glu Ser Glu Ser Gln Lys Gly Glu Phe
Ser Leu Ser Val Leu Asp Gly 145 150 155 gca gtt gta aaa cac tac aga
att aaa aga ctg gat gaa ggg gga ttt 890 Ala Val Val Lys His Tyr Arg
Ile Lys Arg Leu Asp Glu Gly Gly Phe 160 165 170 175 ttt ctc acg cga
aga aga atc ttt tca aca ctg aac gaa ttt gtg agc 938 Phe Leu Thr Arg
Arg Arg Ile Phe Ser Thr Leu Asn Glu Phe Val Ser 180 185 190 cac tac
acc aag aca agt gac ggc ctg tgt gtc aag ctg ggg aaa cca 986 His Tyr
Thr Lys Thr Ser Asp Gly Leu Cys Val Lys Leu Gly Lys Pro 195 200 205
tgc tta aag atc cag gtc cca gct cca ttt gat ttg tcg tat aaa acc
1034 Cys Leu Lys Ile Gln Val Pro Ala Pro Phe Asp Leu Ser Tyr Lys
Thr 210 215 220 gtg gac caa tgg gag ata gac cgc aac tcc ata cag ctt
ctg aag cga 1082 Val Asp Gln Trp Glu Ile Asp Arg Asn Ser Ile Gln
Leu Leu Lys Arg 225 230 235 ttg gga tct ggt cag ttt ggc gaa gta tgg
gaa ggt ctg tgg aac aat 1130 Leu Gly Ser Gly Gln Phe Gly Glu Val
Trp Glu Gly Leu Trp Asn Asn 240 245 250 255 acc act cca gta gca gtg
aaa aca tta aaa cca ggt tca atg gat cca 1178 Thr Thr Pro Val Ala
Val Lys Thr Leu Lys Pro Gly Ser Met Asp Pro 260 265 270 aat gac ttc
ctg agg gag gca cag ata atg aag aac cta aga cat cca 1226 Asn Asp
Phe Leu Arg Glu Ala Gln Ile Met Lys Asn Leu Arg His Pro 275 280 285
aag ctt atc cag ctt tat gct gtt tgc act tta gaa gat cca att tat
1274 Lys Leu Ile Gln Leu Tyr Ala Val Cys Thr Leu Glu Asp Pro Ile
Tyr 290 295 300 att att aca gag ttg atg aga cat gga agt ctg caa gaa
tat ctc caa 1322 Ile Ile Thr Glu Leu Met Arg His Gly Ser Leu Gln
Glu Tyr Leu Gln 305 310 315 aat gac act gga tca aaa atc cat ctg act
caa cag gta gac atg gcg 1370 Asn Asp Thr Gly Ser Lys Ile His Leu
Thr Gln Gln Val Asp Met Ala 320 325 330 335 gca cag gtt gcc tct gga
atg gcc tat ctg gag tct cgg aac tac att 1418 Ala Gln Val Ala Ser
Gly Met Ala Tyr Leu Glu Ser Arg Asn Tyr Ile 340 345 350 cac aga gat
ctg gct gcc aga aat gtc ctc gtt ggt gaa cat aat atc 1466 His Arg
Asp Leu Ala Ala Arg Asn Val Leu Val Gly Glu His Asn Ile 355 360 365
tac aaa gta gca gat ttt gga ctt gcc aga gtt ttt aag gta gat aat
1514 Tyr Lys Val Ala Asp Phe Gly Leu Ala Arg Val Phe Lys Val Asp
Asn 370 375 380 gaa gac atc tat gaa tct aga cac gaa ata aag ctg ccg
gtg aag tgg 1562 Glu Asp Ile Tyr Glu Ser Arg His Glu Ile Lys Leu
Pro Val Lys Trp 385 390 395 act gcg ccc gaa gcc att cgt agt aat aaa
ttc agc att aag tcc gat 1610 Thr Ala Pro Glu Ala Ile Arg Ser Asn
Lys Phe Ser Ile Lys Ser Asp 400 405 410 415 gta tgg tca ttt gga atc
ctt ctt tat gaa atc att act tat ggc aaa 1658 Val Trp Ser Phe Gly
Ile Leu Leu Tyr Glu Ile Ile Thr Tyr Gly Lys 420 425 430 atg cct tac
agt ggt atg aca ggt gcc cag gta atc cag atg ttg gct 1706 Met Pro
Tyr Ser Gly Met Thr Gly Ala Gln Val Ile Gln Met Leu Ala 435 440 445
caa aac tat aga ctt ccg caa cca tcc aac tgt cca cag caa ttt tac
1754 Gln Asn Tyr Arg Leu Pro Gln Pro Ser Asn Cys Pro Gln Gln Phe
Tyr 450 455 460 aac atc atg ttg gag tgc tgg aat gca gag cct aag gaa
cga cct aca 1802 Asn Ile Met Leu Glu Cys Trp Asn Ala Glu Pro Lys
Glu Arg Pro Thr 465 470 475 ttt gag aca ctg cgt tgg aaa ctt gaa gac
tat ttt gaa aca gac tct 1850 Phe Glu Thr Leu Arg Trp Lys Leu Glu
Asp Tyr Phe Glu Thr Asp Ser 480 485 490 495 tca tat tca gat gca aat
aac ttc ata aga tgaacactgg agaagaatat 1900 Ser Tyr Ser Asp Ala Asn
Asn Phe Ile Arg 500 505 caaataataa agtagcaaaa caaattcaaa taatccattc
caaaatacaa tgttatcaac 1960 caactgcaca atcagtttat cctgacatat
tcaagtgata ggataaagtt ggccatgtat 2020 tatgaaaaag attatttgtg
cattttattg actgggcaac actgcaggac agtcaaggtc 2080 atatataatt
gctcactgcc tggaaaatta agcacactaa accaagttat ttttcttttt 2140
aagagatact tacatttcca tttattgttt gaaatgtcgc gatcaagaga atcaacagat
2200 gatagtccaa tttttactca gtgatgactg tgtagcattt tcctgtttac
tgattagagt 2260 ggttattcat tattcctcag attgctgaat cccatcaggc
tgttattatg aaggaatttg 2320 attgctttgc tgcacagcag gacctgtgct
ttgagatttt tttttctctt ttaaaatatc 2380 ctgtaactac aatgatggta
aagccatgtt aaatgacttg attgtacttg gagtaattgc 2440 acattttttt
ctatgcataa aaaaatgatg cagctgttga gaaaacgaag tctttttcat 2500
tttgcagaag gaaatgatgg aatttttctg tacttcagta tgtgtcaact gagagtcata
2560 tacattagtt ttaatctctt aatattgaga atcaggttgc aaaacggatg
agttattatc 2620 tatggaaatg tgagaaatgt ctaatagccc ataaagtctg
agaaataggt atcaaaatag 2680 tttaggaaaa tgagaggaga acagtaggat
tgctgtggcc tagacttctg agtaattaat 2740 aaagaaaaag aagtaccaaa
aaaaaaaaaa 2770 6 505 PRT Unknown Organism Description of Unknown
Organism Megakaryocyte kinase 3 6 Met Ser Asn Ile Cys Gln Arg Leu
Trp Glu Tyr Leu Glu Pro Tyr Leu 1 5 10 15 Pro Cys Leu Ser Thr Glu
Ala Asp Lys Ser Thr Val Ile Glu Asn Pro 20 25 30 Gly Ala Leu Cys
Ser Pro Gln Ser Gln Arg His Gly His Tyr Phe Val 35 40 45 Ala Leu
Phe Asp Tyr Gln Ala Arg Thr Ala Glu Asp Leu Ser Phe Arg 50 55 60
Ala Gly Asp Lys Leu Gln Val Leu Asp Thr Leu His Glu Gly Trp Trp 65
70 75 80 Phe Ala Arg His Leu Glu Lys Arg Arg Asp Gly Ser Ser Gln
Gln Leu 85 90 95 Gln Gly Tyr Ile Pro Ser Asn Tyr Val Ala Glu Asp
Arg Ser Leu Gln 100 105 110 Ala Glu Pro Trp Phe Phe Gly Ala Ile Gly
Arg Ser Asp Ala Glu Lys 115 120 125 Gln Leu Leu Tyr Ser Glu Asn Lys
Thr Gly Ser Phe Leu Ile Arg Glu 130 135 140 Ser Glu Ser Gln Lys Gly
Glu Phe Ser Leu Ser Val Leu Asp Gly Ala 145 150 155 160 Val Val Lys
His Tyr Arg Ile Lys Arg Leu Asp Glu Gly Gly Phe Phe 165 170 175 Leu
Thr Arg Arg Arg Ile Phe Ser Thr Leu Asn Glu Phe Val Ser His 180 185
190 Tyr Thr Lys Thr Ser Asp Gly Leu Cys Val Lys Leu Gly Lys Pro Cys
195 200 205 Leu Lys Ile Gln Val Pro Ala Pro Phe Asp Leu Ser Tyr Lys
Thr Val 210 215 220 Asp Gln Trp Glu Ile Asp Arg Asn Ser Ile Gln Leu
Leu Lys Arg Leu 225 230 235 240 Gly Ser Gly Gln Phe Gly Glu Val Trp
Glu Gly Leu Trp Asn Asn Thr 245 250 255 Thr Pro Val Ala Val Lys Thr
Leu Lys Pro Gly Ser Met Asp Pro Asn 260 265 270 Asp Phe Leu Arg Glu
Ala Gln Ile Met Lys Asn Leu Arg His Pro Lys 275 280 285 Leu Ile Gln
Leu Tyr Ala Val Cys Thr Leu Glu Asp Pro Ile Tyr Ile 290 295 300 Ile
Thr Glu Leu Met Arg His Gly Ser Leu Gln Glu Tyr Leu Gln Asn 305 310
315 320 Asp Thr Gly Ser Lys Ile His Leu Thr Gln Gln Val Asp Met Ala
Ala 325 330 335 Gln Val Ala Ser Gly Met Ala Tyr Leu Glu Ser Arg Asn
Tyr Ile His 340 345 350 Arg Asp Leu Ala Ala Arg Asn Val Leu Val Gly
Glu His Asn Ile Tyr 355 360 365 Lys Val Ala Asp Phe Gly Leu Ala Arg
Val Phe Lys Val Asp Asn Glu 370 375 380 Asp Ile Tyr Glu Ser Arg His
Glu Ile Lys Leu Pro Val Lys Trp Thr 385 390 395 400 Ala Pro Glu Ala
Ile Arg Ser Asn Lys Phe Ser Ile Lys Ser Asp Val 405 410 415 Trp Ser
Phe Gly Ile Leu Leu Tyr Glu Ile Ile Thr Tyr Gly Lys Met 420 425 430
Pro Tyr Ser Gly Met Thr Gly Ala Gln Val Ile Gln Met Leu Ala Gln 435
440 445 Asn Tyr Arg Leu Pro Gln Pro Ser Asn Cys Pro Gln Gln Phe Tyr
Asn 450 455 460 Ile Met Leu Glu Cys Trp Asn Ala Glu Pro Lys Glu Arg
Pro Thr Phe 465 470 475 480 Glu Thr Leu Arg Trp Lys Leu Glu Asp Tyr
Phe Glu Thr Asp Ser Ser 485 490 495 Tyr Ser Asp Ala Asn Asn Phe Ile
Arg 500 505 7 450 PRT Homo sapiens 7 Met Ser Ala Ile Gln Ala Ala
Trp Pro Ser Gly Thr Glu Cys Ile Ala 1 5 10
15 Lys Tyr Asn Phe His Gly Thr Ala Glu Gln Asp Leu Pro Phe Cys Lys
20 25 30 Gly Asp Val Leu Thr Ile Val Ala Val Thr Lys Asp Pro Asn
Trp Tyr 35 40 45 Lys Ala Lys Asn Lys Val Gly Arg Glu Gly Ile Ile
Pro Ala Asn Tyr 50 55 60 Val Gln Lys Arg Glu Gly Val Lys Ala Gly
Thr Lys Leu Ser Leu Met 65 70 75 80 Pro Trp Phe His Gly Lys Ile Thr
Arg Glu Gln Ala Glu Arg Leu Leu 85 90 95 Tyr Pro Pro Glu Thr Gly
Leu Phe Leu Val Arg Glu Ser Thr Asn Tyr 100 105 110 Pro Gly Asp Tyr
Thr Leu Cys Val Ser Cys Asp Gly Lys Val Glu His 115 120 125 Tyr Arg
Ile Met Tyr His Ala Ser Lys Leu Ser Ile Asp Glu Glu Val 130 135 140
Tyr Phe Glu Asn Leu Met Gln Leu Val Glu His Tyr Thr Ser Asp Ala 145
150 155 160 Asp Gly Leu Cys Thr Arg Leu Ile Lys Pro Lys Val Met Glu
Gly Thr 165 170 175 Val Ala Ala Gln Asp Glu Phe Tyr Arg Ser Gly Trp
Ala Leu Asn Met 180 185 190 Lys Glu Leu Lys Leu Leu Gln Thr Ile Gly
Lys Gly Glu Phe Gly Asp 195 200 205 Val Met Leu Gly Asp Tyr Arg Gly
Asn Lys Val Ala Val Lys Cys Ile 210 215 220 Lys Asn Asp Ala Thr Ala
Gln Ala Phe Leu Ala Glu Ala Ser Val Met 225 230 235 240 Thr Gln Leu
Arg His Ser Asn Leu Val Gln Leu Leu Gly Val Ile Val 245 250 255 Glu
Glu Lys Gly Gly Leu Tyr Ile Val Thr Glu Tyr Met Ala Lys Gly 260 265
270 Ser Leu Val Asp Tyr Leu Arg Ser Arg Gly Arg Ser Val Leu Gly Gly
275 280 285 Asp Cys Leu Leu Lys Phe Ser Leu Asp Val Cys Glu Ala Met
Glu Tyr 290 295 300 Leu Glu Gly Asn Asn Phe Val His Arg Asp Leu Ala
Ala Arg Asn Val 305 310 315 320 Leu Val Ser Glu Asp Asn Val Ala Lys
Val Ser Asp Phe Gly Leu Thr 325 330 335 Lys Glu Ala Ser Ser Thr Gln
Asp Thr Gly Lys Leu Pro Val Lys Trp 340 345 350 Thr Ala Pro Glu Ala
Leu Arg Glu Lys Lys Phe Ser Thr Lys Ser Asp 355 360 365 Val Trp Ser
Phe Gly Ile Leu Leu Trp Glu Ile Tyr Ser Phe Gly Arg 370 375 380 Val
Pro Tyr Pro Arg Ile Pro Leu Lys Asp Val Val Pro Arg Val Glu 385 390
395 400 Lys Gly Tyr Lys Met Asp Ala Pro Asp Gly Cys Pro Pro Ala Val
Tyr 405 410 415 Glu Val Met Lys Asn Cys Trp His Leu Asp Ala Ala Met
Arg Pro Ser 420 425 430 Phe Leu Gln Leu Arg Glu Gln Leu Glu His Ile
Lys Thr His Glu Leu 435 440 445 His Leu 450 8 659 PRT Homo sapiens
8 Met Ala Ala Val Ile Leu Glu Ser Ile Phe Leu Lys Arg Ser Gln Gln 1
5 10 15 Lys Lys Lys Thr Ser Pro Leu Asn Phe Lys Lys Arg Leu Phe Leu
Leu 20 25 30 Thr Val His Lys Leu Ser Tyr Tyr Glu Tyr Asp Phe Glu
Arg Gly Arg 35 40 45 Arg Gly Ser Lys Lys Gly Ser Ile Asp Val Glu
Lys Ile Thr Cys Val 50 55 60 Glu Thr Val Val Pro Glu Lys Asn Pro
Pro Pro Glu Arg Gln Ile Pro 65 70 75 80 Arg Arg Gly Glu Glu Ser Ser
Glu Met Glu Gln Ile Ser Ile Ile Glu 85 90 95 Arg Phe Pro Tyr Pro
Phe Gln Val Val Tyr Asp Glu Gly Pro Leu Tyr 100 105 110 Val Phe Ser
Pro Thr Glu Glu Leu Arg Lys Arg Trp Ile His Gln Leu 115 120 125 Lys
Asn Val Ile Arg Tyr Asn Ser Asp Leu Val Gln Lys Tyr His Pro 130 135
140 Cys Phe Trp Ile Asp Gly Gln Tyr Leu Cys Cys Ser Gln Thr Ala Lys
145 150 155 160 Asn Ala Met Gly Cys Gln Ile Leu Glu Asn Arg Asn Gly
Ser Leu Lys 165 170 175 Pro Gly Ser Ser His Arg Lys Thr Lys Lys Pro
Leu Pro Pro Thr Pro 180 185 190 Glu Glu Asp Gln Ile Leu Lys Lys Pro
Leu Pro Pro Glu Pro Ala Ala 195 200 205 Ala Pro Val Ser Thr Ser Glu
Leu Lys Lys Val Val Ala Leu Tyr Asp 210 215 220 Tyr Met Pro Met Asn
Ala Asn Asp Leu Gln Leu Arg Lys Gly Asp Glu 225 230 235 240 Tyr Phe
Ile Leu Glu Glu Ser Asn Leu Pro Trp Trp Arg Ala Arg Asp 245 250 255
Lys Asn Gly Gln Glu Gly Tyr Ile Pro Ser Asn Tyr Val Thr Glu Ala 260
265 270 Glu Asp Ser Ile Glu Met Tyr Glu Trp Tyr Ser Lys His Met Thr
Arg 275 280 285 Ser Gln Ala Glu Gln Leu Leu Lys Gln Glu Gly Lys Glu
Gly Gly Phe 290 295 300 Ile Val Arg Asp Ser Ser Lys Ala Gly Lys Tyr
Thr Val Ser Val Phe 305 310 315 320 Ala Lys Ser Thr Gly Asp Pro Gln
Gly Val Ile Arg His Tyr Val Val 325 330 335 Cys Ser Thr Pro Gln Ser
Gln Tyr Tyr Leu Ala Glu Lys His Leu Phe 340 345 350 Ser Thr Ile Pro
Glu Leu Ile Asn Tyr His Gln His Asn Ser Ala Gly 355 360 365 Leu Ile
Ser Arg Leu Lys Tyr Pro Val Ser Gln Gln Asn Lys Asn Ala 370 375 380
Pro Ser Thr Ala Gly Leu Gly Tyr Gly Ser Trp Glu Ile Asp Pro Lys 385
390 395 400 Asp Leu Thr Phe Leu Lys Glu Leu Gly Thr Gly Gln Phe Gly
Val Val 405 410 415 Lys Tyr Gly Lys Trp Arg Gly Gln Tyr Asp Val Ala
Ile Lys Met Ile 420 425 430 Lys Glu Gly Ser Met Ser Glu Asp Glu Phe
Ile Glu Glu Ala Lys Val 435 440 445 Met Met Asn Leu Ser His Glu Lys
Leu Val Gln Leu Tyr Gly Val Cys 450 455 460 Thr Lys Gln Arg Pro Ile
Phe Ile Ile Thr Glu Tyr Met Ala Asn Gly 465 470 475 480 Cys Leu Leu
Asn Tyr Leu Arg Glu Met Arg His Arg Phe Gln Thr Gln 485 490 495 Gln
Leu Leu Glu Met Cys Lys Asp Val Cys Glu Ala Met Glu Tyr Leu 500 505
510 Glu Ser Lys Gln Phe Leu His Arg Asp Leu Ala Ala Arg Asn Cys Leu
515 520 525 Val Asn Asp Gln Gly Val Val Lys Val Ser Asp Phe Gly Leu
Ser Arg 530 535 540 Tyr Val Leu Asp Asp Glu Tyr Thr Ser Ser Val Gly
Ser Lys Phe Pro 545 550 555 560 Val Arg Trp Ser Pro Pro Glu Val Leu
Met Tyr Ser Lys Phe Ser Ser 565 570 575 Lys Ser Asp Ile Trp Ala Phe
Gly Val Leu Met Trp Glu Ile Tyr Ser 580 585 590 Leu Gly Lys Met Pro
Tyr Glu Arg Phe Thr Asn Ser Glu Thr Ala Glu 595 600 605 His Ile Ala
Gln Gly Leu Arg Leu Tyr Arg Pro His Leu Ala Ser Glu 610 615 620 Lys
Val Tyr Thr Ile Met Tyr Ser Cys Trp His Glu Lys Ala Asp Glu 625 630
635 640 Arg Pro Thr Phe Lys Ile Leu Leu Ser Asn Ile Leu Asp Val Met
Asp 645 650 655 Glu Glu Ser 9 620 PRT Homo sapiens 9 Met Asn Asn
Phe Ile Leu Leu Glu Glu Gln Leu Ile Lys Lys Ser Gln 1 5 10 15 Gln
Lys Arg Arg Thr Ser Pro Ser Asn Phe Lys Val Arg Phe Phe Val 20 25
30 Leu Thr Lys Ala Ser Leu Ala Tyr Phe Glu Asp Arg His Gly Lys Lys
35 40 45 Arg Thr Leu Lys Gly Ser Ile Glu Leu Ser Arg Ile Lys Cys
Val Glu 50 55 60 Ile Val Lys Ser Asp Ile Ser Ile Pro Cys His Tyr
Lys Tyr Pro Phe 65 70 75 80 Gln Val Val His Asp Asn Tyr Leu Leu Tyr
Val Phe Ala Pro Asp Arg 85 90 95 Glu Ser Arg Gln Arg Trp Val Leu
Ala Leu Lys Glu Glu Thr Arg Asn 100 105 110 Asn Asn Ser Leu Val Pro
Lys Tyr His Pro Asn Phe Trp Met Asp Gly 115 120 125 Lys Trp Arg Cys
Cys Ser Gln Leu Glu Lys Leu Ala Thr Gly Cys Ala 130 135 140 Gln Tyr
Asp Pro Thr Lys Asn Ala Ser Lys Lys Pro Leu Pro Pro Thr 145 150 155
160 Pro Glu Asp Asn Arg Arg Pro Leu Trp Glu Pro Glu Glu Thr Val Val
165 170 175 Ile Ala Leu Tyr Asp Tyr Gln Thr Asn Asp Pro Gln Glu Leu
Ala Leu 180 185 190 Arg Arg Asn Glu Glu Tyr Cys Leu Leu Asp Ser Ser
Glu Ile His Trp 195 200 205 Trp Arg Val Gln Asp Arg Asn Gly His Glu
Gly Tyr Val Pro Ser Ser 210 215 220 Tyr Leu Val Glu Lys Ser Pro Asn
Asn Leu Glu Thr Tyr Glu Trp Tyr 225 230 235 240 Asn Lys Ser Ile Ser
Arg Asp Lys Ala Glu Lys Leu Leu Leu Asp Thr 245 250 255 Gly Lys Glu
Gly Ala Phe Met Val Arg Asp Ser Arg Thr Ala Gly Thr 260 265 270 Tyr
Thr Val Ser Val Phe Thr Lys Ala Val Val Ser Glu Asn Asn Pro 275 280
285 Cys Ile Lys His Tyr His Ile Lys Glu Thr Asn Asp Asn Pro Lys Arg
290 295 300 Tyr Tyr Val Ala Glu Lys Tyr Val Phe Asp Ser Ile Pro Leu
Leu Ile 305 310 315 320 Asn Tyr His Gln His Asn Gly Gly Gly Leu Val
Thr Arg Leu Arg Tyr 325 330 335 Pro Val Cys Phe Gly Arg Gln Lys Ala
Pro Val Thr Ala Gly Leu Arg 340 345 350 Tyr Gly Lys Trp Val Ile Asp
Pro Ser Glu Leu Thr Phe Val Gln Glu 355 360 365 Ile Gly Ser Gly Gln
Phe Gly Leu Val His Leu Gly Tyr Trp Leu Asn 370 375 380 Lys Asp Lys
Val Ala Ile Lys Thr Ile Arg Glu Gly Ala Met Ser Glu 385 390 395 400
Glu Asp Phe Ile Glu Glu Ala Glu Val Met Met Lys Leu Ser His Pro 405
410 415 Lys Leu Val Gln Leu Tyr Gly Val Cys Leu Glu Gln Ala Pro Ile
Cys 420 425 430 Leu Val Phe Glu Phe Met Glu His Gly Cys Leu Ser Asp
Tyr Leu Arg 435 440 445 Thr Gln Arg Gly Leu Phe Ala Ala Glu Thr Leu
Leu Gly Met Cys Leu 450 455 460 Asp Val Cys Glu Gly Met Ala Tyr Leu
Glu Glu Ala Cys Val Ile His 465 470 475 480 Arg Asp Leu Ala Ala Arg
Asn Cys Leu Val Gly Glu Asn Gln Val Ile 485 490 495 Lys Val Ser Asp
Phe Gly Met Thr Arg Phe Val Leu Asp Asp Gln Tyr 500 505 510 Thr Ser
Ser Thr Gly Thr Lys Phe Pro Val Lys Trp Ala Ser Pro Glu 515 520 525
Val Phe Ser Phe Ser Arg Tyr Ser Ser Lys Ser Asp Val Trp Ser Phe 530
535 540 Gly Val Leu Met Trp Glu Val Phe Ser Glu Gly Lys Ile Pro Tyr
Glu 545 550 555 560 Asn Arg Ser Asn Ser Glu Val Val Glu Asp Ile Ser
Thr Gly Phe Arg 565 570 575 Leu Tyr Lys Pro Arg Leu Ala Ser Thr His
Val Tyr Gln Ile Met Asn 580 585 590 His Cys Trp Lys Glu Arg Pro Glu
Asp Arg Pro Ala Phe Ser Arg Leu 595 600 605 Leu Arg Gln Leu Ala Glu
Ile Ala Glu Ser Gly Leu 610 615 620 10 527 PRT Mus sp. 10 Met Met
Val Ser Phe Pro Val Lys Ile Asn Phe His Ser Ser Pro Gln 1 5 10 15
Ser Arg Asp Arg Trp Val Lys Lys Leu Lys Glu Glu Ile Lys Asn Asn 20
25 30 Asn Asn Ile Met Ile Lys Tyr His Pro Lys Phe Trp Ala Asp Gly
Ser 35 40 45 Tyr Gln Cys Cys Arg Gln Thr Glu Lys Leu Ala Pro Gly
Cys Glu Lys 50 55 60 Tyr Asn Leu Phe Glu Ser Ser Ile Arg Lys Thr
Leu Pro Pro Ala Pro 65 70 75 80 Glu Ile Lys Lys Arg Arg Pro Pro Pro
Pro Ile Pro Pro Glu Glu Glu 85 90 95 Asn Thr Glu Glu Ile Val Val
Ala Met Tyr Asp Phe Gln Ala Thr Glu 100 105 110 Ala His Asp Leu Arg
Leu Glu Arg Gly Gln Glu Tyr Ile Ile Leu Glu 115 120 125 Lys Asn Asp
Leu His Trp Trp Arg Ala Arg Asp Lys Tyr Gly Trp Tyr 130 135 140 Cys
Arg Asn Thr Asn Arg Ser Lys Ala Glu Gln Leu Leu Arg Thr Glu 145 150
155 160 Asp Lys Glu Gly Gly Phe Met Val Arg Asp Ser Ser Gln Pro Gly
Leu 165 170 175 Tyr Thr Val Ser Leu Tyr Thr Lys Phe Gly Gly Glu Gly
Ser Ser Gly 180 185 190 Phe Arg His Tyr His Ile Lys Glu Thr Ala Thr
Ser Pro Lys Lys Tyr 195 200 205 Tyr Leu Ala Glu Lys His Ala Phe Gly
Ser Ile Pro Glu Ile Ile Glu 210 215 220 Tyr His Lys His Asn Ala Ala
Gly Leu Val Thr Arg Leu Arg Tyr Pro 225 230 235 240 Val Ser Thr Lys
Gly Lys Asn Ala Pro Thr Thr Ala Gly Phe Ser Tyr 245 250 255 Asp Lys
Trp Glu Ile Asn Pro Ser Glu Leu Thr Phe Met Arg Glu Leu 260 265 270
Gly Ser Gly Leu Phe Gly Val Val Arg Leu Gly Lys Trp Arg Ala Gln 275
280 285 Tyr Lys Val Ala Ile Lys Ala Ile Arg Glu Gly Ala Met Cys Glu
Glu 290 295 300 Asp Phe Ile Glu Glu Ala Lys Val Met Met Lys Leu Thr
His Pro Lys 305 310 315 320 Leu Val Gln Leu Tyr Gly Val Cys Thr Gln
Gln Lys Pro Ile Tyr Ile 325 330 335 Val Thr Glu Phe Met Glu Arg Gly
Cys Leu Leu Asn Phe Leu Arg Gln 340 345 350 Arg Gln Gly His Phe Ser
Arg Asp Met Leu Leu Ser Met Cys Gln Asp 355 360 365 Val Cys Glu Gly
Met Glu Tyr Leu Glu Arg Asn Ser Phe Ile His Arg 370 375 380 Asp Leu
Ala Ala Arg Asn Cys Leu Val Asn Glu Ala Gly Val Val Lys 385 390 395
400 Val Ser Asp Phe Gly Met Ala Arg Tyr Val Leu Asp Asp Gln Tyr Thr
405 410 415 Ser Ser Ser Gly Ala Lys Phe Pro Val Lys Trp Cys Pro Pro
Glu Val 420 425 430 Phe Asn Tyr Ser Arg Phe Ser Ser Lys Ser Asp Val
Trp Ser Phe Gly 435 440 445 Val Leu Met Trp Glu Ile Phe Thr Glu Gly
Arg Met Pro Phe Glu Lys 450 455 460 Asn Thr Asn Tyr Glu Val Val Thr
Met Val Thr Arg Gly His Arg Leu 465 470 475 480 His Arg Pro Lys Leu
Ala Thr Lys Tyr Leu Tyr Glu Val Met Leu Arg 485 490 495 Cys Trp Gln
Glu Arg Pro Glu Gly Arg Pro Ser Phe Glu Asp Leu Leu 500 505 510 Arg
Thr Ile Asp Glu Leu Val Glu Cys Glu Glu Thr Phe Gly Arg 515 520 525
11 537 PRT Homo sapiens 11 Met Gly Cys Val Gln Cys Lys Asp Lys Glu
Ala Thr Lys Leu Thr Glu 1 5 10 15 Glu Arg Asp Gly Ser Leu Asn Gln
Ser Ser Gly Tyr Arg Tyr Gly Thr 20 25 30 Asp Pro Thr Pro Gln His
Tyr Pro Ser Phe Gly Val Thr Ser Ile Pro 35 40 45 Asn Tyr Asn Asn
Phe His Ala Ala Gly Gly Gln Gly Leu Thr Val Phe 50 55 60 Gly Gly
Val Asn Ser Ser Ser His Thr Gly Thr Leu Arg Thr Arg Gly 65 70 75 80
Gly Thr Gly Val Thr Leu Phe Val Ala Leu Tyr Asp Tyr Glu Ala Arg 85
90 95 Thr Glu Asp Asp Leu Ser Phe His Lys Gly Glu Lys Phe Gln Ile
Leu 100 105 110 Asn Ser Ser Glu Gly Asp Trp Trp Glu Ala Arg Ser Leu
Thr Thr Gly 115 120 125 Glu Thr Gly Tyr Ile Pro Ser Asn Tyr Val Ala
Pro Val Asp Ser Ile 130 135 140 Gln Ala Glu Glu Trp Tyr Phe Gly Lys
Leu Gly Arg Lys Asp Ala Glu 145 150 155 160 Arg Gln Leu Leu Ser Phe
Gly Asn Pro Arg Gly Thr Phe Leu Ile Arg 165 170 175 Glu Ser Glu Thr
Thr Lys Gly Ala Tyr Ser Leu Ser Ile Arg Asp Trp 180 185 190 Asp Asp
Met
Lys Gly Asp His Val Lys His Tyr Lys Ile Arg Lys Leu 195 200 205 Asp
Asn Gly Gly Tyr Tyr Ile Thr Thr Arg Ala Gln Phe Glu Thr Leu 210 215
220 Gln Gln Leu Val Gln His Tyr Ser Glu Arg Ala Ala Gly Leu Cys Cys
225 230 235 240 Arg Leu Val Val Pro Cys His Lys Gly Met Pro Arg Leu
Thr Asp Leu 245 250 255 Ser Val Lys Thr Lys Asp Val Trp Glu Ile Pro
Arg Glu Ser Leu Gln 260 265 270 Leu Ile Lys Arg Leu Gly Asn Gly Gln
Phe Gly Glu Val Trp Met Gly 275 280 285 Thr Trp Asn Gly Asn Thr Lys
Val Ala Ile Lys Thr Leu Lys Pro Gly 290 295 300 Thr Met Ser Pro Glu
Ser Phe Leu Glu Glu Ala Gln Ile Met Lys Lys 305 310 315 320 Leu Lys
His Asp Lys Leu Val Gln Leu Tyr Ala Val Val Ser Glu Glu 325 330 335
Pro Ile Tyr Ile Val Thr Glu Tyr Met Asn Lys Gly Ser Leu Leu Asp 340
345 350 Phe Leu Lys Asp Gly Glu Gly Arg Ala Leu Lys Leu Pro Asn Leu
Val 355 360 365 Asp Met Ala Ala Gln Val Ala Ala Gly Met Ala Tyr Ile
Glu Arg Met 370 375 380 Asn Tyr Ile His Arg Asp Leu Arg Ser Ala Asn
Ile Leu Val Gly Asn 385 390 395 400 Gly Leu Ile Cys Lys Ile Ala Asp
Phe Gly Leu Ala Arg Leu Ile Glu 405 410 415 Asp Asn Glu Tyr Thr Ala
Arg Gln Gly Ala Lys Phe Pro Ile Lys Trp 420 425 430 Thr Ala Pro Glu
Ala Ala Leu Tyr Gly Arg Phe Thr Ile Lys Ser Asp 435 440 445 Val Trp
Ser Phe Gly Ile Leu Leu Thr Glu Leu Val Thr Lys Gly Arg 450 455 460
Val Pro Tyr Pro Gly Met Asn Asn Arg Glu Val Leu Glu Gln Val Glu 465
470 475 480 Arg Gly Tyr Arg Met Pro Cys Pro Gln Asp Cys Pro Ile Ser
Leu His 485 490 495 Glu Leu Met Ile His Cys Trp Lys Lys Asp Pro Glu
Glu Arg Pro Thr 500 505 510 Phe Glu Tyr Leu Gln Ser Phe Leu Glu Asp
Tyr Phe Thr Ala Thr Glu 515 520 525 Pro Gln Tyr Gln Pro Gly Glu Asn
Leu 530 535 12 536 PRT Gallus gallus 12 Met Gly Cys Val His Cys Lys
Glu Lys Ile Ser Gly Lys Gly Gln Gly 1 5 10 15 Gly Ser Gly Thr Gly
Thr Pro Ala His Pro Pro Ser Gln Tyr Asp Pro 20 25 30 Asp Pro Thr
Gln Leu Ser Gly Ala Phe Thr His Ile Pro Asp Phe Asn 35 40 45 Asn
Phe His Ala Ala Ala Val Ser Pro Pro Val Pro Phe Ser Gly Pro 50 55
60 Gly Phe Tyr Pro Cys Asn Thr Leu Gln Ala His Ser Ser Ile Thr Gly
65 70 75 80 Gly Gly Val Thr Leu Phe Ile Ala Leu Tyr Asp Tyr Glu Ala
Arg Thr 85 90 95 Glu Asp Asp Leu Ser Phe Gln Lys Gly Glu Lys Phe
His Ile Ile Asn 100 105 110 Asn Thr Glu Gly Asp Trp Trp Glu Ala Arg
Ser Leu Ser Ser Gly Ala 115 120 125 Thr Gly Tyr Ile Pro Ser Asn Tyr
Val Ala Pro Val Asp Ser Ile Gln 130 135 140 Ala Glu Glu Trp Tyr Phe
Gly Lys Ile Gly Arg Lys Asp Ala Glu Arg 145 150 155 160 Gln Leu Leu
Cys His Gly Asn Cys Arg Gly Thr Phe Leu Ile Arg Glu 165 170 175 Ser
Glu Thr Thr Lys Gly Ala Tyr Ser Leu Ser Ile Arg Asp Trp Asp 180 185
190 Glu Ala Lys Gly Asp His Val Lys His Tyr Lys Ile Arg Lys Leu Asp
195 200 205 Ser Gly Gly Tyr Tyr Ile Thr Thr Arg Ala Gln Phe Asp Thr
Ile Gln 210 215 220 Gln Leu Val Gln His Tyr Ile Glu Arg Ala Ala Gly
Leu Cys Cys Arg 225 230 235 240 Leu Ala Val Pro Cys Pro Lys Gly Thr
Pro Lys Leu Ala Asp Leu Ser 245 250 255 Val Lys Thr Lys Asp Val Trp
Glu Ile Pro Arg Glu Ser Leu Gln Leu 260 265 270 Leu Gln Lys Leu Gly
Asn Gly Gln Phe Gly Glu Val Trp Met Gly Thr 275 280 285 Trp Asn Gly
Thr Thr Lys Val Ala Val Lys Thr Leu Lys Pro Gly Thr 290 295 300 Met
Ser Pro Glu Ala Phe Leu Glu Glu Ala Gln Ile Met Lys Arg Leu 305 310
315 320 Arg His Asp Lys Leu Val Gln Leu Tyr Ala Val Val Ser Glu Glu
Pro 325 330 335 Ile Tyr Ile Val Thr Glu Phe Met Ser Gln Gly Ser Leu
Leu Asp Phe 340 345 350 Leu Lys Asp Gly Asp Gly Arg Tyr Leu Lys Leu
Pro Gln Leu Val Asp 355 360 365 Met Ala Ala Gln Ile Ala Ala Gly Met
Ala Tyr Ile Glu Arg Met Asn 370 375 380 Tyr Ile His Arg Asp Leu Arg
Ala Ala Asn Ile Leu Val Gly Asp Asn 385 390 395 400 Leu Val Cys Lys
Ile Ala Asp Phe Gly Leu Ala Arg Leu Ile Glu Asp 405 410 415 Asn Glu
Tyr Thr Ala Arg Gln Gly Ala Lys Phe Pro Ile Lys Trp Thr 420 425 430
Ala Pro Glu Ala Ala Leu Phe Gly Lys Phe Thr Ile Lys Ser Asp Val 435
440 445 Trp Ser Phe Gly Ile Leu Leu Thr Glu Leu Val Thr Lys Gly Arg
Val 450 455 460 Pro Tyr Pro Gly Met Asn Asn Arg Glu Val Leu Glu Gln
Val Glu Arg 465 470 475 480 Gly Tyr Arg Met Gln Cys Pro Gly Gly Cys
Pro Pro Ser Leu His Asp 485 490 495 Val Met Val Gln Cys Trp Lys Arg
Glu Pro Glu Glu Arg Pro Thr Phe 500 505 510 Glu Tyr Leu Gln Ser Phe
Leu Glu Asp Tyr Phe Thr Ala Thr Glu Pro 515 520 525 Gln Tyr Gln Pro
Gly Asp Asn Gln 530 535 13 536 PRT Homo sapiens 13 Met Gly Ser Asn
Lys Ser Lys Pro Lys Asp Ala Ser Gln Arg Arg Arg 1 5 10 15 Ser Leu
Glu Pro Ala Glu Asn Val His Gly Ala Gly Gly Gly Ala Phe 20 25 30
Pro Ala Ser Gln Thr Pro Ser Lys Pro Ala Ser Ala Asp Gly His Arg 35
40 45 Gly Pro Ser Ala Ala Phe Ala Pro Ala Ala Ala Glu Pro Lys Leu
Phe 50 55 60 Gly Gly Phe Asn Ser Ser Asp Thr Val Thr Ser Pro Gln
Arg Ala Gly 65 70 75 80 Pro Leu Ala Gly Gly Val Thr Thr Phe Val Ala
Leu Tyr Asp Tyr Glu 85 90 95 Ser Arg Thr Glu Thr Asp Leu Ser Phe
Lys Lys Gly Glu Arg Leu Gln 100 105 110 Ile Val Asn Asn Thr Glu Gly
Asp Trp Trp Leu Ala His Ser Leu Ser 115 120 125 Thr Gly Gln Thr Gly
Tyr Ile Pro Ser Asn Tyr Val Ala Pro Ser Asp 130 135 140 Ser Ile Gln
Ala Glu Glu Trp Tyr Phe Gly Lys Ile Thr Arg Arg Glu 145 150 155 160
Ser Glu Arg Leu Leu Leu Asn Ala Glu Asn Pro Arg Gly Thr Phe Leu 165
170 175 Val Arg Glu Ser Glu Thr Thr Lys Gly Ala Tyr Cys Leu Ser Val
Ser 180 185 190 Asp Phe Asp Asn Ala Lys Gly Leu Asn Val Lys His Tyr
Lys Ile Arg 195 200 205 Lys Leu Asp Ser Gly Gly Phe Tyr Ile Thr Ser
Arg Thr Gln Phe Asn 210 215 220 Ser Leu Gln Gln Leu Val Ala Tyr Tyr
Ser Lys His Ala Asp Gly Leu 225 230 235 240 Cys His Arg Leu Thr Thr
Val Cys Pro Thr Ser Lys Pro Gln Thr Gln 245 250 255 Gly Leu Ala Lys
Asp Ala Trp Glu Ile Pro Arg Glu Ser Leu Arg Leu 260 265 270 Glu Val
Lys Leu Gly Gln Gly Cys Phe Gly Glu Val Trp Met Gly Thr 275 280 285
Trp Asn Gly Thr Thr Arg Val Ala Ile Lys Thr Leu Lys Pro Gly Thr 290
295 300 Met Ser Pro Glu Ala Phe Leu Gln Glu Ala Gln Val Met Lys Lys
Leu 305 310 315 320 Arg His Glu Lys Leu Val Gln Leu Tyr Ala Val Val
Ser Glu Glu Pro 325 330 335 Ile Tyr Ile Val Thr Glu Tyr Met Ser Lys
Gly Ser Leu Leu Asp Phe 340 345 350 Leu Lys Gly Glu Thr Gly Lys Tyr
Leu Arg Leu Pro Gln Leu Val Asp 355 360 365 Met Ala Ala Gln Ile Ala
Ser Gly Met Ala Tyr Val Glu Arg Met Asn 370 375 380 Tyr Val His Arg
Asp Leu Arg Ala Ala Asn Ile Leu Val Gly Glu Asn 385 390 395 400 Leu
Val Cys Lys Val Ala Asp Phe Gly Leu Ala Arg Leu Ile Glu Asp 405 410
415 Asn Glu Tyr Thr Ala Arg Gln Gly Ala Lys Phe Pro Ile Lys Trp Thr
420 425 430 Ala Pro Glu Ala Ala Leu Tyr Gly Arg Phe Thr Ile Lys Ser
Asp Val 435 440 445 Trp Ser Phe Gly Ile Leu Leu Thr Glu Leu Thr Thr
Lys Gly Arg Val 450 455 460 Pro Tyr Pro Gly Met Val Asn Arg Glu Val
Leu Asp Gln Val Glu Arg 465 470 475 480 Gly Tyr Arg Met Pro Cys Pro
Pro Glu Cys Pro Glu Ser Leu His Asp 485 490 495 Leu Met Cys Gln Cys
Trp Arg Lys Glu Pro Glu Glu Arg Pro Thr Phe 500 505 510 Glu Tyr Leu
Gln Ala Phe Leu Glu Asp Tyr Phe Thr Ser Thr Glu Pro 515 520 525 Gln
Tyr Gln Pro Gly Glu Asn Leu 530 535 14 543 PRT Homo sapiens 14 Met
Gly Cys Ile Lys Ser Lys Glu Asn Lys Ser Pro Ala Ile Lys Tyr 1 5 10
15 Arg Pro Glu Asn Thr Pro Glu Pro Val Ser Thr Ser Val Ser His Tyr
20 25 30 Gly Ala Glu Pro Thr Thr Val Ser Pro Cys Pro Ser Ser Ser
Ala Lys 35 40 45 Gly Thr Ala Val Asn Phe Ser Ser Leu Ser Met Thr
Pro Phe Gly Gly 50 55 60 Ser Ser Gly Val Thr Pro Phe Gly Gly Ala
Ser Ser Ser Phe Ser Val 65 70 75 80 Val Pro Ser Ser Tyr Pro Ala Gly
Leu Thr Gly Gly Val Thr Ile Phe 85 90 95 Val Ala Leu Tyr Asp Tyr
Glu Ala Arg Thr Thr Glu Asp Leu Ser Phe 100 105 110 Lys Lys Gly Glu
Arg Phe Gln Ile Ile Asn Asn Thr Glu Gly Asp Trp 115 120 125 Trp Glu
Ala Arg Ser Ile Ala Thr Gly Lys Asn Gly Tyr Ile Pro Ser 130 135 140
Asn Tyr Val Ala Pro Ala Asp Ser Ile Gln Ala Glu Glu Trp Tyr Phe 145
150 155 160 Gly Lys Met Gly Arg Lys Asp Ala Glu Arg Leu Leu Leu Asn
Pro Gly 165 170 175 Asn Gln Arg Gly Ile Phe Leu Val Arg Glu Ser Glu
Thr Thr Lys Gly 180 185 190 Ala Tyr Ser Leu Ser Ile Arg Asp Trp Asp
Glu Ile Arg Gly Asp Asn 195 200 205 Val Lys His Tyr Lys Ile Arg Lys
Leu Asp Asn Gly Gly Tyr Tyr Ile 210 215 220 Thr Thr Arg Ala Gln Phe
Asp Thr Leu Gln Lys Leu Val Lys His Tyr 225 230 235 240 Thr Glu His
Ala Asp Gly Leu Cys His Lys Leu Thr Thr Val Cys Pro 245 250 255 Thr
Val Lys Pro Gln Thr Gln Gly Leu Ala Lys Asp Ala Trp Glu Ile 260 265
270 Pro Arg Glu Ser Leu Arg Leu Glu Val Lys Leu Gly Gln Gly Cys Phe
275 280 285 Gly Glu Val Trp Met Gly Thr Trp Asn Gly Thr Thr Lys Val
Ala Ile 290 295 300 Lys Thr Leu Lys Pro Gly Thr Met Met Pro Glu Ala
Phe Leu Gln Glu 305 310 315 320 Ala Gln Ile Met Lys Lys Leu Arg His
Asp Lys Leu Val Pro Leu Tyr 325 330 335 Ala Val Val Ser Glu Glu Pro
Ile Tyr Ile Val Thr Glu Phe Met Ser 340 345 350 Lys Gly Ser Leu Leu
Asp Phe Leu Lys Glu Gly Asp Gly Lys Tyr Leu 355 360 365 Lys Leu Pro
Gln Leu Val Asp Met Ala Ala Gln Ile Ala Asp Gly Met 370 375 380 Ala
Tyr Ile Glu Arg Met Asn Tyr Ile His Arg Asp Leu Arg Ala Ala 385 390
395 400 Asn Ile Leu Val Gly Glu Asn Leu Val Cys Lys Ile Ala Asp Phe
Gly 405 410 415 Leu Ala Arg Leu Ile Glu Asp Asn Glu Tyr Thr Ala Arg
Gln Gly Ala 420 425 430 Lys Phe Pro Ile Lys Trp Thr Ala Pro Glu Ala
Ala Leu Tyr Gly Arg 435 440 445 Phe Thr Ile Lys Ser Asp Val Trp Ser
Phe Gly Ile Leu Gln Thr Glu 450 455 460 Leu Val Thr Lys Gly Arg Val
Pro Tyr Pro Gly Met Val Asn Arg Glu 465 470 475 480 Val Leu Glu Gln
Val Glu Arg Gly Tyr Arg Met Pro Cys Pro Gln Gly 485 490 495 Cys Pro
Glu Ser Leu His Glu Leu Met Asn Leu Cys Trp Lys Lys Asp 500 505 510
Pro Asp Glu Arg Pro Thr Phe Glu Tyr Ile Gln Ser Phe Leu Glu Asp 515
520 525 Tyr Phe Thr Ala Thr Glu Pro Gln Tyr Gln Pro Gly Glu Asn Leu
530 535 540 15 529 PRT Homo sapiens 15 Met Gly Cys Val Phe Cys Lys
Lys Leu Glu Pro Val Ala Thr Ala Lys 1 5 10 15 Glu Asp Ala Gly Leu
Glu Gly Asp Phe Arg Ser Tyr Gly Ala Ala Asp 20 25 30 His Tyr Gly
Pro Asp Pro Thr Lys Ala Arg Pro Ala Ser Ser Phe Ala 35 40 45 His
Ile Pro Asn Tyr Ser Asn Phe Ser Ser Gln Ala Ile Asn Pro Gly 50 55
60 Phe Leu Asp Ser Gly Thr Ile Arg Gly Val Ser Gly Ile Gly Val Thr
65 70 75 80 Leu Phe Ile Ala Leu Tyr Asp Tyr Glu Ala Arg Thr Glu Asp
Asp Leu 85 90 95 Thr Phe Thr Lys Gly Glu Lys Phe His Ile Leu Asn
Asn Thr Glu Gly 100 105 110 Asp Trp Trp Glu Ala Arg Ser Leu Ser Ser
Gly Lys Thr Gly Cys Ile 115 120 125 Pro Ser Asn Tyr Val Ala Pro Val
Asp Ser Ile Gln Ala Glu Glu Trp 130 135 140 Tyr Phe Gly Lys Ile Gly
Arg Lys Asp Ala Glu Arg Gln Leu Leu Ser 145 150 155 160 Pro Gly Asn
Pro Gln Gly Ala Phe Leu Ile Arg Glu Ser Glu Thr Thr 165 170 175 Lys
Gly Ala Tyr Ser Leu Ser Ile Arg Asp Trp Asp Gln Thr Arg Gly 180 185
190 Asp His Val Lys His Tyr Lys Ile Arg Lys Leu Asp Met Gly Gly Tyr
195 200 205 Tyr Ile Thr Thr Arg Val Gln Phe Asn Ser Val Gln Glu Leu
Val Gln 210 215 220 His Tyr Met Glu Val Asn Asp Gly Leu Cys Asn Leu
Leu Ile Ala Pro 225 230 235 240 Cys Thr Ile Met Lys Pro Gln Thr Leu
Gly Leu Ala Lys Asp Ala Trp 245 250 255 Glu Ile Ser Arg Ser Ser Ile
Thr Leu Glu Arg Arg Leu Gly Thr Gly 260 265 270 Cys Phe Gly Asp Val
Trp Leu Gly Thr Trp Asn Gly Ser Thr Lys Val 275 280 285 Ala Val Lys
Thr Leu Lys Pro Gly Thr Met Ser Pro Lys Ala Phe Leu 290 295 300 Glu
Glu Ala Gln Val Met Lys Leu Leu Arg His Asp Lys Leu Val Gln 305 310
315 320 Leu Tyr Ala Val Val Ser Glu Glu Pro Ile Tyr Ile Val Thr Glu
Phe 325 330 335 Met Cys His Gly Ser Leu Leu Asp Phe Leu Lys Asn Pro
Glu Gly Gln 340 345 350 Asp Leu Arg Leu Pro Gln Leu Val Asp Met Ala
Ala Gln Val Ala Glu 355 360 365 Gly Met Ala Tyr Met Glu Arg Met Asn
Tyr Ile His Arg Asp Leu Arg 370 375 380 Ala Ala Asn Ile Leu Val Gly
Glu Arg Leu Ala Cys Lys Ile Ala Asp 385 390 395 400 Phe Gly Leu Ala
Arg Leu Ile Lys Asp Asp Glu Tyr Asn Pro Cys Gln 405 410 415 Gly Ser
Lys Phe Pro Ile Lys Trp Thr Ala Pro Glu Ala Ala Leu Phe 420 425 430
Gly Arg Phe Thr Ile Lys Ser Asp Val Trp Ser Phe Gly Ile Leu Leu 435
440 445 Thr Glu Leu Ile Thr Lys Gly Arg Ile Pro Tyr Pro Gly Met Asn
Lys 450 455 460 Arg Glu Val Leu Glu Gln Val Glu Gln Gly Tyr His Met
Pro Cys Pro 465 470 475 480 Pro Gly
Cys Pro Ala Ser Leu Tyr Glu Ala Met Glu Gln Thr Trp Arg 485 490 495
Leu Asp Pro Glu Glu Arg Pro Thr Phe Glu Tyr Leu Gln Ser Phe Leu 500
505 510 Glu Asp Tyr Phe Thr Ser Ala Glu Pro Gln Tyr Gln Pro Gly Asp
Gln 515 520 525 Thr 16 512 PRT Homo sapiens 16 Met Gly Cys Ile Lys
Ser Lys Gly Lys Asp Ser Leu Ser Asp Asp Gly 1 5 10 15 Val Asp Leu
Lys Thr Gln Pro Val Arg Asn Thr Glu Arg Thr Ile Tyr 20 25 30 Val
Arg Asp Pro Thr Ser Asn Lys Gln Gln Arg Pro Val Pro Glu Ser 35 40
45 Gln Leu Leu Pro Gly Gln Arg Phe Gln Thr Lys Asp Pro Glu Glu Gln
50 55 60 Gly Asp Ile Val Val Ala Leu Tyr Pro Tyr Asp Gly Ile His
Pro Asp 65 70 75 80 Asp Leu Ser Phe Lys Lys Gly Glu Lys Met Lys Val
Leu Glu Glu His 85 90 95 Gly Glu Trp Trp Lys Ala Lys Ser Leu Leu
Thr Lys Lys Glu Gly Phe 100 105 110 Ile Pro Ser Asn Tyr Val Ala Lys
Leu Asn Thr Leu Glu Thr Glu Glu 115 120 125 Trp Phe Phe Lys Asp Ile
Thr Arg Lys Asp Ala Glu Arg Gln Leu Leu 130 135 140 Ala Pro Gly Asn
Ser Ala Gly Ala Phe Leu Ile Arg Glu Ser Glu Thr 145 150 155 160 Leu
Lys Gly Ser Phe Ser Leu Ser Val Arg Asp Phe Asp Pro Val His 165 170
175 Gly Asp Val Ile Lys His Tyr Lys Ile Arg Ser Leu Asp Asn Gly Gly
180 185 190 Tyr Tyr Ile Ser Pro Arg Ile Thr Phe Pro Cys Ile Ser Asp
Met Ile 195 200 205 Lys His Tyr Gln Lys Gln Ala Asp Gly Leu Cys Arg
Arg Leu Glu Lys 210 215 220 Ala Cys Ile Ser Pro Lys Pro Gln Lys Pro
Trp Asp Lys Asp Ala Trp 225 230 235 240 Glu Ile Pro Arg Glu Ser Ile
Lys Leu Val Lys Arg Leu Gly Ala Gly 245 250 255 Gln Phe Gly Glu Val
Trp Met Gly Tyr Tyr Asn Asn Ser Thr Lys Val 260 265 270 Ala Val Lys
Thr Leu Lys Pro Gly Thr Met Ser Val Gln Ala Phe Leu 275 280 285 Glu
Glu Ala Asn Leu Met Lys Thr Leu Gln His Asp Lys Leu Val Arg 290 295
300 Leu Tyr Ala Val Val Thr Arg Glu Glu Pro Ile Tyr Ile Ile Thr Glu
305 310 315 320 Tyr Met Ala Lys Gly Ser Leu Leu Asp Phe Leu Lys Ser
Asp Glu Gly 325 330 335 Gly Lys Val Leu Leu Pro Lys Leu Ile Asp Phe
Ser Ala Gln Ile Ala 340 345 350 Glu Gly Met Ala Tyr Ile Glu Arg Lys
Asn Tyr Ile His Arg Asp Leu 355 360 365 Arg Ala Ala Asn Val Leu Val
Ser Glu Ser Leu Met Cys Lys Ile Ala 370 375 380 Asp Phe Gly Leu Ala
Arg Val Ile Glu Asp Asn Glu Tyr Thr Ala Arg 385 390 395 400 Glu Gly
Ala Lys Phe Pro Ile Lys Trp Thr Ala Pro Glu Ala Ile Asn 405 410 415
Phe Gly Cys Phe Thr Ile Lys Ser Asp Val Trp Ser Phe Gly Ile Leu 420
425 430 Leu Tyr Glu Ile Val Thr Tyr Gly Lys Ile Pro Tyr Pro Gly Arg
Thr 435 440 445 Asn Ala Asp Val Met Thr Ala Leu Ser Gln Gly Tyr Arg
Met Pro Arg 450 455 460 Val Glu Asn Cys Pro Asp Glu Leu Tyr Asp Ile
Met Lys Met Cys Trp 465 470 475 480 Lys Glu Lys Ala Glu Glu Arg Pro
Thr Phe Asp Tyr Leu Gln Ser Val 485 490 495 Leu Asp Asp Phe Tyr Thr
Ala Thr Glu Gly Gln Tyr Gln Gln Gln Pro 500 505 510 17 505 PRT Homo
sapiens 17 Met Gly Ser Met Lys Ser Lys Phe Leu Gln Val Gly Gly Asn
Thr Phe 1 5 10 15 Ser Lys Thr Glu Thr Ser Ala Ser Pro His Cys Pro
Val Tyr Val Pro 20 25 30 Asp Pro Thr Ser Thr Ile Lys Pro Gly Pro
Asn Ser His Asn Ser Asn 35 40 45 Thr Pro Gly Ile Arg Glu Ala Gly
Ser Glu Asp Ile Ile Val Val Ala 50 55 60 Leu Tyr Asp Tyr Glu Ala
Ile His His Glu Asp Leu Ser Phe Gln Lys 65 70 75 80 Gly Asp Gln Met
Val Val Leu Glu Glu Ser Gly Glu Trp Trp Lys Ala 85 90 95 Arg Ser
Leu Ala Thr Arg Lys Glu Gly Tyr Ile Pro Ser Asn Tyr Val 100 105 110
Ala Arg Val Asp Ser Leu Glu Thr Glu Glu Trp Phe Phe Lys Gly Ile 115
120 125 Ser Arg Lys Asp Ala Glu Arg Gln Leu Leu Ala Pro Gly Asn Met
Leu 130 135 140 Gly Ser Phe Met Ile Arg Asp Ser Glu Thr Thr Lys Gly
Ser Tyr Ser 145 150 155 160 Leu Ser Val Arg Asp Tyr Asp Pro Arg Gln
Gly Asp Thr Val Lys His 165 170 175 Tyr Lys Ile Arg Thr Leu Asp Asn
Gly Gly Phe Tyr Ile Ser Pro Arg 180 185 190 Ser Thr Phe Ser Thr Leu
Gln Glu Leu Val Asp His Tyr Lys Lys Gly 195 200 205 Asn Asp Gly Leu
Cys Gln Lys Leu Ser Val Pro Cys Met Ser Ser Lys 210 215 220 Pro Gln
Lys Pro Trp Glu Lys Asp Ala Trp Glu Ile Pro Arg Glu Ser 225 230 235
240 Leu Lys Leu Glu Lys Lys Leu Gly Ala Gly Gln Phe Gly Glu Val Trp
245 250 255 Met Ala Thr Tyr Asn Lys His Thr Lys Val Ala Val Lys Thr
Met Lys 260 265 270 Pro Gly Ser Met Ser Val Glu Ala Phe Leu Ala Glu
Ala Asn Val Met 275 280 285 Lys Thr Leu Gln His Asp Lys Leu Val Lys
Leu His Ala Val Val Thr 290 295 300 Lys Glu Pro Ile Tyr Ile Ile Thr
Glu Phe Met Ala Lys Gly Ser Leu 305 310 315 320 Leu Asp Phe Leu Lys
Ser Asp Glu Gly Ser Lys Gln Pro Leu Pro Lys 325 330 335 Leu Ile Asp
Phe Ser Ala Gln Ile Ala Glu Gly Met Ala Phe Ile Glu 340 345 350 Gln
Arg Asn Tyr Ile His Arg Asp Leu Arg Ala Ala Asn Ile Leu Val 355 360
365 Ser Ala Ser Leu Val Cys Lys Ile Ala Asp Phe Gly Leu Ala Arg Val
370 375 380 Ile Glu Asp Asn Glu Tyr Thr Ala Arg Glu Gly Ala Lys Phe
Pro Ile 385 390 395 400 Lys Trp Thr Ala Pro Glu Ala Ile Asn Phe Gly
Ser Phe Thr Ile Lys 405 410 415 Ser Asp Val Trp Ser Phe Gly Ile Leu
Leu Met Glu Ile Val Thr Tyr 420 425 430 Gly Arg Ile Pro Tyr Pro Gly
Met Ser Asn Pro Glu Val Ile Arg Ala 435 440 445 Leu Glu Arg Gly Tyr
Arg Met Pro Arg Pro Glu Asn Cys Pro Glu Glu 450 455 460 Leu Tyr Asn
Ile Met Met Arg Cys Trp Lys Asn Arg Pro Glu Glu Arg 465 470 475 480
Pro Thr Phe Glu Tyr Ile Gln Ser Val Leu Asp Asp Phe Tyr Thr Ala 485
490 495 Thr Glu Ser Gln Tyr Gln Gln Gln Pro 500 505 18 509 PRT Homo
sapiens 18 Met Gly Cys Gly Cys Ser Ser His Pro Glu Asp Asp Trp Met
Glu Asn 1 5 10 15 Ile Asp Val Cys Glu Asn Cys His Tyr Pro Ile Val
Pro Leu Asp Gly 20 25 30 Lys Gly Thr Leu Leu Ile Arg Asn Gly Ser
Glu Val Arg Asp Pro Leu 35 40 45 Val Thr Tyr Glu Gly Ser Asn Pro
Pro Ala Ser Pro Leu Gln Asp Asn 50 55 60 Leu Val Ile Ala Leu His
Ser Tyr Glu Pro Ser His Asp Gly Asp Leu 65 70 75 80 Gly Phe Glu Lys
Gly Glu Gln Leu Arg Ile Leu Glu Gln Ser Gly Glu 85 90 95 Trp Trp
Lys Ala Gln Ser Leu Thr Thr Gly Gln Glu Gly Phe Ile Pro 100 105 110
Phe Asn Phe Val Ala Lys Ala Asn Ser Leu Glu Pro Glu Pro Trp Phe 115
120 125 Phe Lys Asn Leu Ser Arg Lys Asp Ala Glu Arg Gln Leu Leu Ala
Pro 130 135 140 Gly Asn Thr His Gly Ser Phe Leu Ile Arg Glu Ser Glu
Ser Thr Ala 145 150 155 160 Gly Ser Phe Ser Leu Ser Val Arg Asp Phe
Asp Gln Asn Gln Gly Glu 165 170 175 Val Val Lys His Tyr Lys Ile Arg
Asn Leu Asp Asn Gly Gly Phe Tyr 180 185 190 Ile Ser Pro Arg Ile Thr
Phe Pro Gly Leu His Glu Leu Val Arg His 195 200 205 Tyr Thr Asn Ala
Ser Asp Gly Leu Cys Thr Arg Leu Ser Arg Pro Cys 210 215 220 Gln Thr
Gln Lys Pro Gln Lys Pro Trp Trp Glu Asp Glu Trp Glu Val 225 230 235
240 Pro Arg Glu Thr Leu Lys Leu Val Glu Arg Leu Gly Ala Gly Gln Phe
245 250 255 Gly Glu Val Trp Met Gly Tyr Tyr Asn Gly His Thr Lys Val
Ala Val 260 265 270 Lys Ser Leu Lys Gln Gly Ser Met Ser Pro Asp Ala
Phe Leu Ala Glu 275 280 285 Ala Asn Leu Met Lys Gln Leu Gln His Gln
Arg Leu Val Arg Leu Tyr 290 295 300 Ala Val Val Thr Gln Glu Pro Ile
Tyr Ile Ile Thr Glu Tyr Met Glu 305 310 315 320 Asn Gly Ser Leu Val
Asp Phe Leu Lys Thr Pro Ser Gly Ile Lys Leu 325 330 335 Thr Ile Asn
Lys Leu Leu Asp Met Ala Ala Gln Ile Ala Glu Gly Met 340 345 350 Ala
Phe Ile Glu Glu Arg Asn Tyr Ile His Arg Asp Leu Arg Ala Ala 355 360
365 Asn Ile Leu Val Ser Asp Thr Leu Ser Cys Lys Ile Ala Asp Phe Gly
370 375 380 Leu Ala Arg Leu Ile Glu Asp Asn Glu Tyr Thr Ala Arg Glu
Gly Ala 385 390 395 400 Lys Phe Pro Ile Lys Trp Thr Ala Pro Glu Ala
Ile Asn Tyr Gly Thr 405 410 415 Phe Thr Ile Lys Ser Asp Val Trp Ser
Phe Gly Ile Leu Leu Thr Glu 420 425 430 Ile Val Thr His Gly Arg Ile
Pro Tyr Pro Gly Met Thr Asn Pro Glu 435 440 445 Val Ile Gln Asn Leu
Glu Arg Gly Tyr Arg Met Val Arg Pro Asp Asn 450 455 460 Cys Pro Glu
Glu Leu Tyr Gln Leu Met Arg Leu Cys Trp Lys Glu Arg 465 470 475 480
Pro Glu Asp Arg Pro Thr Phe Asp Tyr Leu Arg Ser Val Leu Glu Asp 485
490 495 Phe Phe Thr Ala Thr Glu Gly Gln Tyr Gln Pro Gln Pro 500 505
19 499 PRT Mus sp. 19 Met Gly Leu Leu Ser Ser Lys Arg Gln Val Ser
Glu Lys Gly Lys Gly 1 5 10 15 Trp Ser Pro Val Lys Ile Arg Thr Gln
Asp Lys Ala Pro Pro Pro Leu 20 25 30 Pro Pro Leu Val Val Phe Asn
His Leu Ala Pro Pro Ser Pro Asn Gln 35 40 45 Asp Pro Asp Glu Glu
Glu Arg Phe Val Val Ala Leu Phe Asp Tyr Ala 50 55 60 Ala Val Asn
Asp Arg Asp Leu Gln Val Leu Lys Gly Glu Lys Leu Gln 65 70 75 80 Val
Leu Arg Ser Thr Gly Asp Trp Trp Leu Ala Arg Ser Leu Val Thr 85 90
95 Gly Arg Glu Gly Tyr Val Pro Ser Asn Phe Val Ala Pro Val Glu Thr
100 105 110 Leu Glu Val Glu Lys Trp Phe Phe Arg Thr Ile Ser Arg Lys
Asp Ala 115 120 125 Glu Arg Gln Leu Leu Ala Pro Met Asn Lys Ala Gly
Ser Phe Leu Ile 130 135 140 Arg Glu Ser Glu Ser Asn Lys Gly Ala Phe
Ser Leu Ser Val Lys Asp 145 150 155 160 Ile Thr Thr Gln Gly Glu Val
Val Lys His Tyr Lys Ile Arg Ser Leu 165 170 175 Asp Asn Gly Gly Tyr
Tyr Ile Ser Pro Arg Ile Thr Phe Pro Thr Leu 180 185 190 Gln Ala Leu
Val Gln His Tyr Ser Lys Lys Gly Asp Gly Leu Cys Gln 195 200 205 Lys
Leu Thr Leu Pro Cys Val Asn Leu Ala Pro Lys Asn Leu Trp Ala 210 215
220 Gln Asp Glu Trp Glu Ile Pro Arg Gln Ser Leu Lys Leu Val Arg Lys
225 230 235 240 Leu Gly Ser Gly Gln Phe Gly Glu Val Trp Met Gly Tyr
Tyr Lys Asn 245 250 255 Asn Met Lys Val Ala Ile Lys Thr Leu Lys Glu
Gly Thr Met Ser Pro 260 265 270 Glu Ala Phe Leu Gly Glu Ala Asn Val
Met Lys Thr Leu Gln His Glu 275 280 285 Arg Leu Val Arg Leu Tyr Ala
Val Val Thr Arg Glu Pro Ile Tyr Ile 290 295 300 Val Thr Glu Tyr Met
Ala Arg Gly Cys Leu Leu Asp Phe Leu Lys Thr 305 310 315 320 Asp Glu
Gly Ser Arg Leu Ser Leu Pro Arg Leu Ile Asp Met Ser Ala 325 330 335
Gln Val Ala Glu Gly Met Ala Tyr Ile Glu Arg Met Asn Ser Ile His 340
345 350 Arg Asp Leu Arg Ala Ala Asn Ile Leu Val Ser Glu Thr Leu Cys
Cys 355 360 365 Lys Ile Ala Asp Phe Gly Leu Ala Arg Ile Ile Asp Ser
Glu Tyr Thr 370 375 380 Ala Gln Glu Gly Ala Lys Phe Pro Ile Lys Trp
Thr Ala Pro Glu Ala 385 390 395 400 Ile His Phe Gly Val Phe Thr Ile
Lys Ala Asp Val Trp Ser Phe Gly 405 410 415 Val Leu Leu Met Val Ile
Val Thr Tyr Gly Arg Val Pro Tyr Pro Gly 420 425 430 Met Ser Asn Pro
Glu Val Ile Arg Ser Leu Glu His Gly Tyr Arg Met 435 440 445 Pro Cys
Pro Glu Thr Cys Pro Pro Glu Leu Tyr Asn Asp Ile Ile Thr 450 455 460
Glu Cys Trp Arg Gly Arg Pro Glu Glu Arg Pro Thr Phe Glu Phe Leu 465
470 475 480 Gln Ser Val Leu Glu Asp Phe Tyr Thr Ala Thr Glu Gly Gln
Tyr Glu 485 490 495 Leu Gln Pro 20 28 DNA Artificial Sequence
modified_base (14) A, T, C, G, other or unknown 20 ggaattccca
ymgnrayytn rcnrcnmg 28 21 26 DNA Artificial Sequence modified_base
(12) A, T, C, G, other or unknown 21 ggaattccrw rnswccanac stcnsa
26 22 15 PRT Artificial Sequence Description of Artificial Sequence
Synthetic peptide 22 Gly Gln Asp Ala Asp Gly Ser Thr Ser Pro Arg
Ser Gln Glu Pro 1 5 10 15 23 16 PRT Artificial Sequence Description
of Artificial Sequence Synthetic peptide 23 Gln Gln Leu Leu Ser Ser
Ile Glu Pro Leu Arg Glu Lys Asp Lys His 1 5 10 15 24 6 PRT
Artificial Sequence Description of Artificial Sequence Illustrative
peptide 24 Ser Asp Val Trp Ser Xaa 1 5
* * * * *